Translational and Computational Research on Solid and Hematological Cancer
Publications 2025
DNA glycosylases Ogg1 and Mutyh influence gene expression of PRC2 targets associated with cognition
82 (1), 307
DOI 10.1007/s00018-025-05730-9, PubMed 40779073
Pan-carcinoma sialyl-Tn-targeting expands CAR therapy to solid tumors
6 (9), 102350
DOI 10.1016/j.xcrm.2025.102350, PubMed 40925376
SMUG1 DNA glycosylase modulates reward behaviour through regulation of olfactory receptor gene expression
53 (14)
DOI 10.1093/nar/gkaf722, PubMed 40716776
High-grade B-cell lymphoma, not otherwise specified: an LLMPP study
9 (21), 5409-5422
DOI 10.1182/bloodadvances.2025016651, PubMed 40674706
Deep Learning Can Accurately Predict the Prognosis of Gynecologic Smooth Muscle Tumors of Uncertain Malignant Potential: A Multicenter Pilot Study
105 (10), 104211
DOI 10.1016/j.labinv.2025.104211, PubMed 40602459
Effect of substantial lymphovascular space invasion on location of first disease recurrence in surgical stage I endometrioid endometrial adenocarcinoma
35 (4), 101651
DOI 10.1016/j.ijgc.2025.101651, PubMed 40055122
Erratum to 'Effect of substantial lymphovascular space invasion on location of first disease recurrence in surgical stage I endometrioid endometrial adenocarcinoma' [International Journal of Gynecological Cancer Volume 35 Issue 4 (2025) 101651]
35 (9), 101962
DOI 10.1016/j.ijgc.2025.101962, PubMed 40483226
The Diagnostic Role of TFF1, TFF3, FOXA1, CA XII and TRPS1 in Serous Effusions
36 (4), 408-417
DOI 10.1111/cyt.13489, PubMed 40170411
EpiMapper: A new tool for analyzing high-throughput sequencing from CUT&Tag
186, 109692
DOI 10.1016/j.compbiomed.2025.109692, PubMed 39832438
Data set for reporting of peripheral neuroblastic tumours: recommendations from the international collaboration on cancer reporting (ICCR)
87 (3), 343-356
DOI 10.1111/his.15424, PubMed 39989174
Biomarker-adapted treatment in high-risk large B-cell lymphoma
9 (5), e70139
DOI 10.1002/hem3.70139, PubMed 40357216
Prognostic value of assessing ctDNA in patients with endometrial carcinoma - an international multicenter study
195, 98-105
DOI 10.1016/j.ygyno.2025.03.002, PubMed 40081113
Chromatin landscape in paired human visceral and subcutaneous adipose tissue and its impact on clinical variables in obesity
114, 105653
DOI 10.1016/j.ebiom.2025.105653, PubMed 40118008
Harmonization of Reporting for Detection of ALK Genetic Alterations in Neuroblastoma: A SIOPEN Biology Study
(in press)
DOI 10.1016/j.jmoldx.2025.09.007, PubMed 41110766
A Distinctive DICER1-Related Wilms-Like Uterine Tumor: A Report of Eight Cases
38 (12), 100895 (in press)
DOI 10.1016/j.modpat.2025.100895, PubMed 40998289
Integrated analysis of differential intra-chromosomal community interactions: A study of breast cancer
167, 103180
DOI 10.1016/j.artmed.2025.103180, PubMed 40449144
Publications 2024
Characterization of tumor microenvironment and cell interaction patterns in testicular and diffuse large B-cell lymphomas
110 (6), 1339-1350
DOI 10.3324/haematol.2024.286267, PubMed 39665214
Multi-omics profiling of longitudinal samples reveals early genomic changes in follicular lymphoma
14 (1), 147
DOI 10.1038/s41408-024-01124-5, PubMed 39191762
Expression of PRAME in high-grade serous carcinoma is associated with higher residual disease volume and Occludin expression
266, 155787
DOI 10.1016/j.prp.2024.155787, PubMed 39709875
Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16
12 (4)
DOI 10.1136/jitc-2023-008179, PubMed 38604812
Comprehensive molecular characterization of early stage grade 3 endometrioid endometrial adenocarcinoma
189, 138-145
DOI 10.1016/j.ygyno.2024.07.677, PubMed 39126895
Molecular characteristics of tubo-ovarian carcinosarcoma at different anatomic locations
485 (6), 1053-1061
DOI 10.1007/s00428-024-03821-9, PubMed 38733380
Stathmin is an Independent Prognostic Marker of Poor Outcome in Uterine Leiomyosarcoma
44 (1), 56-66
DOI 10.1097/PGP.0000000000001030, PubMed 38847524
Endometrial carcinomas with ambiguous histology often harbor TP53 mutations
486 (4), 697-705
DOI 10.1007/s00428-024-03912-7, PubMed 39235515
Correction: Whole exome sequencing of high-risk neuroblastoma identifies novel non-synonymous variants
19 (7), e0306687
DOI 10.1371/journal.pone.0306687, PubMed 38950054
Evolutionary mode and timing of dissemination of high-grade serous carcinomas
9 (3)
DOI 10.1172/jci.insight.170423, PubMed 38175731
Predicting regulatory mutations and their target genes by new computational integrative analysis: A study of follicular lymphoma
178, 108787
DOI 10.1016/j.compbiomed.2024.108787, PubMed 38901187
Altered Genome-Wide DNA Methylation in the Duodenum of Common Variable Immunodeficiency Patients
44 (6), 133
DOI 10.1007/s10875-024-01726-5, PubMed 38780872
A novel multiscale framework for delineating cancer evolution from subclonal compositions
582, 111743
DOI 10.1016/j.jtbi.2024.111743, PubMed 38307450
Publications 2023
External multicentre validation of pseudomyxoma peritonei PSOGI-Ki67 classification
49 (8), 1481-1488
DOI 10.1016/j.ejso.2023.03.206, PubMed 36935222
Claudin-10 is a new candidate prognostic marker in metastatic high-grade serous carcinoma
482 (6), 975-982
DOI 10.1007/s00428-023-03541-6, PubMed 37067588
Lymphovascular invasion and p16 expression are independent prognostic factors in stage I vulvar squamous cell carcinoma
484 (6), 951-963
DOI 10.1007/s00428-023-03670-y, PubMed 37843640
Occludin is overexpressed in tubo-ovarian high-grade serous carcinoma compared to mesothelioma and is a marker of tumor progression and chemoresistance
41 (1), 69-76
DOI 10.1007/s10585-023-10251-5, PubMed 38141113
Clinical significance of L1CAM expression in metastatic tubo-ovarian high-grade serous carcinoma
176, 76-81
DOI 10.1016/j.ygyno.2023.07.004, PubMed 37478615
Molecular characteristics of low-grade serous carcinoma in effusions
34 (2), 99-105
DOI 10.1111/cyt.13207, PubMed 36609991
Molecular features for timely cancer diagnosis and treatment - tumors of the ovary, fallopian tube and endometrium
484 (2), 339-351
DOI 10.1007/s00428-023-03710-7, PubMed 38099957
Novel insights into the pathogenesis of follicular lymphoma by molecular profiling of localized and systemic disease forms
37 (10), 2058-2065
DOI 10.1038/s41375-023-01995-w, PubMed 37563306
Characterization and clinical impact of the tumor microenvironment in post-transplant aggressive B-cell lymphomas
108 (11), 3044-3057
DOI 10.3324/haematol.2023.282831, PubMed 37259566
Proteomics uncovers molecular features for relapse risk stratification in patients with diffuse large B-cell lymphoma
13 (1), 161
DOI 10.1038/s41408-023-00931-6, PubMed 37884514
Genetic Pathways in Peritoneal Mesothelioma Tumorigenesis
20 (4), 363-374
DOI 10.21873/cgp.20388, PubMed 37400148
Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma
7 (23), 7216-7230
DOI 10.1182/bloodadvances.2023010158, PubMed 37695745
Endometrial Pipelle Biopsy Computer-Aided Diagnosis: A Feasibility Study
37 (2), 100417
DOI 10.1016/j.modpat.2023.100417, PubMed 38154654
Identifying functional regulatory mutation blocks by integrating genome sequencing and transcriptome data
26 (8), 107266
DOI 10.1016/j.isci.2023.107266, PubMed 37520692
Publications 2022
abc4pwm: affinity based clustering for position weight matrices in applications of DNA sequence analysis
23 (1), 83
DOI 10.1186/s12859-022-04615-z, PubMed 35240993
Endometrial Carcinoma: Molecular Cytogenetics and Transcriptomic Profile
14 (14)
DOI 10.3390/cancers14143536, PubMed 35884597
Clinicopathological prognostic parameters in patients with tubo-ovarian carcinoma effusions
33 (4), 479-492
DOI 10.1111/cyt.13126, PubMed 35398934
Mapping nucleosome and chromatin architectures: A survey of computational methods
20, 3955-3962
DOI 10.1016/j.csbj.2022.07.037, PubMed 35950186
Integrating whole genome sequencing, methylation, gene expression, topological associated domain information in regulatory mutation prediction: A study of follicular lymphoma
20, 1726-1742
DOI 10.1016/j.csbj.2022.03.023, PubMed 35495111
Comparison of the Idylla™ MSI assay with the Promega™ MSI Analysis System and immunohistochemistry on formalin-fixed paraffin-embedded tissue of endometrial carcinoma: results from an international, multicenter study
480 (5), 1031-1039
DOI 10.1007/s00428-022-03291-x, PubMed 35124717
Humanized Ovarian Cancer Patient-Derived Xenografts for Improved Preclinical Evaluation of Immunotherapies
14 (13)
DOI 10.3390/cancers14133092, PubMed 35804867
Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup
12 (1), 12420
DOI 10.1038/s41598-022-16455-1, PubMed 35859155
AXL inhibition improves BRAF-targeted treatment in melanoma
12 (1), 5076
DOI 10.1038/s41598-022-09078-z, PubMed 35332208
Exosome Secretion and Epithelial-Mesenchymal Transition in Ovarian Cancer Are Regulated by Phospholipase D
23 (21)
DOI 10.3390/ijms232113286, PubMed 36362078
A Novel Cryptic t(2;3)(p21;q25) Translocation Fuses the WWTR1 and PRKCE Genes in Uterine Leiomyoma With 3q- as the Sole Visible Chromosome Abnormality
19 (5), 636-646
DOI 10.21873/cgp.20348, PubMed 35985686
Fusion of the HMGA2 and BNC2 Genes in Uterine Leiomyoma With t(9;12)(p22;q14)
36 (6), 2654-2661
DOI 10.21873/invivo.13000, PubMed 36309352
Whole exome sequencing of high-risk neuroblastoma identifies novel non-synonymous variants
17 (8), e0273280
DOI 10.1371/journal.pone.0273280, PubMed 36037157
Integrating digital pathology with transcriptomic and epigenomic tools for predicting metastatic uterine tumor aggressiveness
10, 1052098
DOI 10.3389/fcell.2022.1052098, PubMed 36467415
Serine metabolism remodeling after platinum-based chemotherapy identifies vulnerabilities in a subgroup of resistant ovarian cancers
13 (1), 4578
DOI 10.1038/s41467-022-32272-6, PubMed 35931688
Publications 2021
Anti-Angiogenic Treatment in Pseudomyxoma Peritonei-Still a Strong Preclinical Rationale
Cancers, 13 (11), 2819
DOI 10.3390/cancers13112819
Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma
Haematologica, 106 (3), 718-729
DOI 10.3324/haematol.2019.243626
Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1)
39 (30), 3377-3390
DOI 10.1200/JCO.21.00086, PubMed 34115544
Primary uterine ectomesenchymoma harboring a DICER1 mutation: case report with molecular analysis
479 (2), 419-424
DOI 10.1007/s00428-021-03057-x, PubMed 33595736
Repurposing F-18-FMISO as a PET tracer for translational imaging of nitroreductase-based gene directed enzyme prodrug therapy
Theranostics, 11 (12), 6044-6057
DOI 10.7150/thno.55092
Update on Sentinel Lymph Node Biopsy in Surgical Staging of Endometrial Carcinoma
10 (14)
DOI 10.3390/jcm10143094, PubMed 34300260
Peptide vaccine targeting mutated GNAS: a potential novel treatment for pseudomyxoma peritonei
9 (10)
DOI 10.1136/jitc-2021-003109, PubMed 34711663
Comparison of Five Near-Infrared Fluorescent Folate Conjugates in an Ovarian Cancer Model
25 (1), 144-155
DOI 10.1007/s11307-021-01685-y, PubMed 34888759
Nuclear IL-33 restrains the early conversion of fibroblasts to an extracellular matrix-secreting phenotype
11 (1), 108
DOI 10.1038/s41598-020-80509-5, PubMed 33420328
Splice-Variant Knock-Out of TGFβ Receptors Perturbates the Proteome of Ovarian Carcinoma Cells
22 (23)
DOI 10.3390/ijms222312647, PubMed 34884451
MX2 mediates establishment of interferon response profile, regulates XAF1, and can sensitize melanoma cells to targeted therapy
Cancer Med., 10 (8), 2840-2854
DOI 10.1002/cam4.3846
Evaluation of Deep Learning Architectures for Complex Immunofluorescence Nuclear Image Segmentation
IEEE Trans. Med. Imaging, 40 (7), 1934-1949
DOI 10.1109/TMI.2021.3069558
Hi-C profiling of cancer spheroids identifies 3D-growth-specific chromatin interactions in breast cancer endocrine resistance
13 (1), 175
DOI 10.1186/s13148-021-01167-6, PubMed 34535185
Characterizing the Invasive Tumor Front of Aggressive Uterine Adenocarcinoma and Leiomyosarcoma
Front. Cell. Dev. Biol., 9, 670185
DOI 10.3389/fcell.2021.670185
Publications 2020
Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group
38 (31), 3685-3697
DOI 10.1200/JCO.18.02132, PubMed 32903140
Age Inherently Links to Histology to Define Histoprognostic Classification of Peripheral Neuroblastic Tumors
38 (31), 3719-3720
DOI 10.1200/JCO.20.01839, PubMed 32931395
Role of the Exosome Secretion Machinery in Ovarian Carcinoma: In Vitro and In Vivo Models
J. Oncol., 2020, 4291827
DOI 10.1155/2020/4291827
Mutation analysis and genomic imbalances of cells found in effusion fluids from patients with ovarian cancer
20 (3), 2273-2279
DOI 10.3892/ol.2020.11782, PubMed 32782545
Expression of Wnt pathway molecules is associated with disease outcome in metastatic high-grade serous carcinoma
477 (2), 249-258
DOI 10.1007/s00428-019-02737-z, PubMed 31900634
Molecular testing on serous effusions
49 (5), 640-646
DOI 10.1002/dc.24392, PubMed 32023012
Expression of palladin is associated with disease progression in metastatic high-grade serous carcinoma
31 (6), 572-578
DOI 10.1111/cyt.12895, PubMed 32741023
The phosphatase PTPN1/PTP1B is a candidate marker of better chemotherapy response in metastatic high-grade serous carcinoma
32 (2), 161-168
DOI 10.1111/cyt.12921, PubMed 33025675
Expression of the cancer stem cell marker SSEA1 is associated with poor survival in metastatic high-grade serous carcinoma
477 (5), 677-685
DOI 10.1007/s00428-020-02850-4, PubMed 32472195
The clinical, morphological, and genetic heterogeneity of endometrial stromal sarcoma
476 (4), 489-490
DOI 10.1007/s00428-020-02762-3, PubMed 31993772
Death domain-associated protein (DAXX) expression is associated with poor survival in metastatic high-grade serous carcinoma
477 (6), 857-864
DOI 10.1007/s00428-020-02842-4, PubMed 32533344
Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy
29 (3), 1199-1213
DOI 10.1016/j.ymthe.2020.11.019, PubMed 33212301
HMST-Seq-Analyzer: A new python tool for differential methylation and hydroxymethylation analysis in various DNA methylation sequencing data
18, 2877-2889
DOI 10.1016/j.csbj.2020.09.038, PubMed 33163148
The Biological Role of the Long Non-coding RNA LINK-A in Ovarian Carcinoma
40 (12), 6677-6684
DOI 10.21873/anticanres.14691, PubMed 33288561
The Biological and Clinical Role of the Long Non-Coding RNA LOC642852 in Ovarian Carcinoma
21 (15)
DOI 10.3390/ijms21155237, PubMed 32718068
Soluble AXL as a marker of disease progression and survival in melanoma
15 (1), e0227187
DOI 10.1371/journal.pone.0227187, PubMed 31917795
The DLBCL90 gene-expression assay identifies double-hit lymphomas with high sensitivity in patients from two phase II clinical trials with high-risk diffuse large B-cell lymphoma
2 (1), 104-108
DOI 10.1002/jha2.109, PubMed 35846101
CD24-targeted intraoperative fluorescence image-guided surgery leads to improved cytoreduction of ovarian cancer in a preclinical orthotopic surgical model
56, 102783
DOI 10.1016/j.ebiom.2020.102783, PubMed 32454402
An annotated fluorescence image dataset for training nuclear segmentation methods
7 (1), 262
DOI 10.1038/s41597-020-00608-w, PubMed 32782410
Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis
4 (9), 1906-1915
DOI 10.1182/bloodadvances.2020001518, PubMed 32380536
Prognostic implications of the microenvironment for follicular lymphoma under immunomodulation therapy
189 (4), 707-717
DOI 10.1111/bjh.16414, PubMed 32012230
Chromosome Translocation t(14;21)(q11;q22) Activates Both OLIG1 and OLIG2 in Pediatric T-cell Lymphoblastic Malignancies and May Signify Adverse Prognosis
17 (1), 41-48
DOI 10.21873/cgp.20166, PubMed 31882550
Exploring the potential effect of paricalcitol on markers of inflammation in de novo renal transplant recipients
15 (12), e0243759
DOI 10.1371/journal.pone.0243759, PubMed 33326471
Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction study
59 (7), 733-740
DOI 10.1080/0284186X.2020.1742377, PubMed 32208873
IGAP-integrative genome analysis pipeline reveals new gene regulatory model associated with nonspecific TF-DNA binding affinity
18, 1270-1286
DOI 10.1016/j.csbj.2020.05.024, PubMed 32612751
Spatial and temporal changes in follicle distribution in the human ovarian cortex
42 (2), 375-383
DOI 10.1016/j.rbmo.2020.10.013, PubMed 33309389
Fifteen Years’ Experience with Vulvar Verrucous Carcinoma at a Single Norwegian Academic Cancer Center
Journal of Gynecology and Women Healthcare, 2 (2), 1-4
PublikaID 489
Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers
80 (20), 4514-4526
DOI 10.1158/0008-5472.CAN-19-3971, PubMed 32859605
11q Deletion or ALK Activity Curbs DLG2 Expression to Maintain an Undifferentiated State in Neuroblastoma
32 (12), 108171
DOI 10.1016/j.celrep.2020.108171, PubMed 32966799
Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series
4 (9), 1859-1866
DOI 10.1182/bloodadvances.2019001325, PubMed 32374878
The 3D genomic landscape of differential response to EGFR/HER2 inhibition in endocrine-resistant breast cancer cells
1863 (11), 194631
DOI 10.1016/j.bbagrm.2020.194631, PubMed 32956836
Modeling and analysis of Hi-C data by HiSIF identifies characteristic promoter-distal loops
12 (1), 69
DOI 10.1186/s13073-020-00769-8, PubMed 32787954
Author Correction: Temporal dynamic reorganization of 3D chromatin architecture in hormone-induced breast cancer and endocrine resistance
11 (1), 1967
DOI 10.1038/s41467-020-15789-6, PubMed 32313124
Publications 2019
BayesPI-BAR2: A New Python Package for Predicting Functional Non-coding Mutations in Cancer Patient Cohorts
10, 282
DOI 10.3389/fgene.2019.00282, PubMed 31001324
Integrated Molecular Analysis of Undifferentiated Uterine Sarcomas Reveals Clinically Relevant Molecular Subtypes
25 (7), 2155-2165
DOI 10.1158/1078-0432.CCR-18-2792, PubMed 30617134
Molecular characterization of carcinosarcomas arising in the uterus and ovaries
10 (38), 3614-3624
DOI 10.18632/oncotarget.26942, PubMed 31217897
MGMT promoter methylation is a rare epigenetic change in malignant effusions
31 (1), 12-15
DOI 10.1111/cyt.12782, PubMed 31808217
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
Ann. Oncol., 30 (5), 672-705
DOI 10.1093/annonc/mdz062
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
Int. J. Gynecol. Cancer, 29 (4), 728-760
DOI 10.1136/ijgc-2019-000308
Biomarkers of drug resistance in ovarian cancer - an update
19 (6), 469-476
DOI 10.1080/14737159.2019.1618187, PubMed 31075061
Results of multigene panel testing in familial cancer cases without genetic cause demonstrated by single gene testing
9 (1), 18555
DOI 10.1038/s41598-019-54517-z, PubMed 31811167
Targeting AXL and the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Melanoma
19 (3), 895-905
DOI 10.1158/1535-7163.MCT-19-0290, PubMed 31871265
p38 MAPK activation through B7-H3-mediated DUSP10 repression promotes chemoresistance
9 (1), 5839
DOI 10.1038/s41598-019-42303-w, PubMed 30967582
A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases
12 (7), 951-958
DOI 10.1016/j.tranon.2019.04.001, PubMed 31096111
ImmunoPeCa trial: Long-term outcome following intraperitoneal MOC31PE immunotoxin treatment in colorectal peritoneal metastasis
47 (1), 134-138
DOI 10.1016/j.ejso.2019.04.014, PubMed 31036394
TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma
7 (3), 355-362
DOI 10.1158/2326-6066.CIR-18-0351, PubMed 30659053
MX 2 is a novel regulator of cell cycle in melanoma cells
33 (3), 446-457
DOI 10.1111/pcmr.12837, PubMed 31660681
Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma
3 (8), 1230-1243
DOI 10.1182/bloodadvances.2018029678, PubMed 30979721
Integrative genomic analysis of peritoneal malignant mesothelioma: understanding a case with extraordinary chemotherapy response
5 (2)
DOI 10.1101/mcs.a003566, PubMed 30862609
High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations
38 Suppl 1 (Iss 1 Suppl 1), S40-S63
DOI 10.1097/PGP.0000000000000491, PubMed 30550483
Diverse Effects of Lysophosphatidic Acid Receptors on Ovarian Cancer Signaling Pathways
2019, 7547469
DOI 10.1155/2019/7547469, PubMed 31636669
Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain
7 (5), 701-706
DOI 10.1158/2326-6066.CIR-18-0777, PubMed 30804006
SOX2 and SOX9 are markers of clinically aggressive disease in metastatic high-grade serous carcinoma
153 (3), 651-660
DOI 10.1016/j.ygyno.2019.03.099, PubMed 30904337
Papilloma of the Fallopian Tube: A Rare Gynecologic Neoplasm Harboring a BRAF (c.1799T>A) Mutation (V600E)
38 (5), 459-463
DOI 10.1097/PGP.0000000000000526, PubMed 29851866
Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer
47, 184-194
DOI 10.1016/j.ebiom.2019.08.055, PubMed 31492560
Temporal dynamic reorganization of 3D chromatin architecture in hormone-induced breast cancer and endocrine resistance
10 (1), 1522
DOI 10.1038/s41467-019-09320-9, PubMed 30944316
Publications 2018
Identification of novel cyclin gene fusion transcripts in endometrioid ovarian carcinomas
143 (6), 1379-1387
DOI 10.1002/ijc.31418, PubMed 29633253
The microRNA miR-192/215 family is upregulated in mucinous ovarian carcinomas
8 (1), 11069
DOI 10.1038/s41598-018-29332-7, PubMed 30038317
Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study
118 (11), 1502-1512
DOI 10.1038/s41416-018-0098-6, PubMed 29755120
Identification of an EPC2-PHF1 fusion transcript in low-grade endometrial stromal sarcoma
9 (27), 19203-19208
DOI 10.18632/oncotarget.24969, PubMed 29721194
Expression and clinical role of the dipeptidyl peptidases DPP8 and DPP9 in ovarian carcinoma
474 (2), 177-185
DOI 10.1007/s00428-018-2487-x, PubMed 30467600
Efficacy of the Nordic and the MSKCC chemotherapy protocols on the overall and progression-free survival in intracranial PCNSL
73, 25-32
DOI 10.1016/j.bcmd.2018.08.005, PubMed 30217760
Circulating tumor cells and cell-free nucleic acids in patients with gynecological malignancies
473 (4), 395-403
DOI 10.1007/s00428-018-2447-5, PubMed 30145616
Expression, activation and clinical relevance of CHK1 and CHK2 in metastatic high-grade serous carcinoma
150 (1), 136-142
DOI 10.1016/j.ygyno.2018.05.007, PubMed 29804637
Expression of 14-3-3 sigma and eta proteins is unrelated to survival in metastatic high-grade serous carcinoma
126 (4), 309-313
DOI 10.1111/apm.12816, PubMed 29464778
The diagnostic role of BAP1 in serous effusions
79, 122-126
DOI 10.1016/j.humpath.2018.05.012, PubMed 29802871
Expression and clinical role of long non-coding RNA in high-grade serous carcinoma
148 (3), 559-566
DOI 10.1016/j.ygyno.2018.01.004, PubMed 29310950
Soluble AXL is ubiquitously present in malignant serous effusions
152 (2), 408-415
DOI 10.1016/j.ygyno.2018.11.012, PubMed 30448261
Three-dimensional analysis reveals altered chromatin interaction by enhancer inhibitors harbors TCF7L2-regulated cancer gene signature
120 (3), 3056-3070
DOI 10.1002/jcb.27449, PubMed 30548288
The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy
183 (2), 225-234
DOI 10.1111/bjh.15518, PubMed 30080252
Evaluation of Memorial Sloan-Kettering Cancer Center and International Extranodal Lymphoma Study Group prognostic scoring systems to predict Overall Survival in intracranial Primary CNS lymphoma
8 (3), e00928
DOI 10.1002/brb3.928, PubMed 29541540
The role of surgery in intracranial PCNSL
41 (4), 1037-1044
DOI 10.1007/s10143-018-0946-0, PubMed 29383600
White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk
168 (5), 326-334
DOI 10.7326/M17-0101, PubMed 29335712
Can the classification of low-grade endometrial stromal tumors still be improved?
473 (6), 663-664
DOI 10.1007/s00428-018-2474-2, PubMed 30367239
Is deep brain involvement in intracranial primary central nervous system lymphoma of importance for penetration of chemotherapeutic agents?
60 (7), 703-713
DOI 10.1007/s00234-018-2038-9, PubMed 29804159
Activity and clinical relevance of autotaxin and lysophosphatidic acid pathways in high-grade serous carcinoma
473 (4), 463-470
DOI 10.1007/s00428-018-2418-x, PubMed 30032361
Inhibition of Endothelial NOTCH1 Signaling Attenuates Inflammation by Reducing Cytokine-Mediated Histone Acetylation at Inflammatory Enhancers
38 (4), 854-869
DOI 10.1161/ATVBAHA.117.310388, PubMed 29449332
Clinical Outcome of Patients With High-Risk Endometrial Carcinoma After Treatment With Chemotherapy Only
28 (9), 1789-1795
DOI 10.1097/IGC.0000000000001356, PubMed 30365455
Evaluation of CHK1 activation in vulvar squamous cell carcinoma and its potential as a therapeutic target in vitro
7 (8), 3955-3964
DOI 10.1002/cam4.1638, PubMed 29963769
Publications 2017
Genomic imbalances are involved in miR-30c and let-7a deregulation in ovarian tumors: implications for HMGA2 expression
8 (13), 21554-21560
DOI 10.18632/oncotarget.15795, PubMed 28423547
MOC31PE immunotoxin - targeting peritoneal metastasis from epithelial ovarian cancer
Oncotarget, 8 (37), 61800-61809
DOI 10.18632/oncotarget.18694
Predicting Variation of DNA Shape Preferences in Protein-DNA Interaction in Cancer Cells with a New Biophysical Model
Genes, 8 (9), 233
DOI 10.3390/genes8090233
Integrative whole-genome sequence analysis reveals roles of regulatory mutations in BCL6 and BCL2 in follicular lymphoma
7 (1), 7040
DOI 10.1038/s41598-017-07226-4, PubMed 28765546
Recurrent fusion transcripts in squamous cell carcinomas of the vulva
8 (10), 16843-16850
DOI 10.18632/oncotarget.15167, PubMed 28186972
RNA-sequencing identifies novel GREB1-NCOA2 fusion gene in a uterine sarcoma with the chromosomal translocation t(2;8)(p25;q13)
57 (4), 176-181
DOI 10.1002/gcc.22518, PubMed 29218853
Neuron navigator-2 and cyclin D2 are new candidate prognostic markers in uterine sarcoma
471 (3), 355-362
DOI 10.1007/s00428-017-2172-5, PubMed 28643014
Molecular characteristics of uterine sarcomas
Expert Rev. Mol. Diagn., 17 (5), 515-522
DOI 10.1080/14737159.2017.1311790
The diagnostic role of PTEN and ARID1A in serous effusions
472 (3), 425-432
DOI 10.1007/s00428-017-2273-1, PubMed 29170871
Novel Treatment with Intraperitoneal MOC31PE Immunotoxin in Colorectal Peritoneal Metastasis: Results From the ImmunoPeCa Phase 1 Trial
Ann. Surg. Oncol., 24 (7), 1916-1922
DOI 10.1245/s10434-017-5814-6
TGF beta splicing and canonical pathway activation in high-grade serous carcinoma
Virchows Arch., 470 (6), 665-678
DOI 10.1007/s00428-017-2127-x
Validation of a Mitotic Index Cutoff as a Prognostic Marker in Undifferentiated Uterine Sarcomas
41 (9), 1231-1237
DOI 10.1097/PAS.0000000000000894, PubMed 28622181
Phospholipase D messenger RNA expression and clinical role in high-grade serous carcinoma
Hum. Pathol., 62, 115-121
DOI 10.1016/j.humpath.2016.12.023
T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling
24 (4), 870-881
DOI 10.1158/1078-0432.CCR-17-2337, PubMed 29217528
ZC3H7B-BCOR high-grade endometrial stromal sarcomas: a report of 17 cases of a newly defined entity
31 (4), 674-684
DOI 10.1038/modpathol.2017.162, PubMed 29192652
Metabolic reprogramming is associated with flavopiridol resistance in prostate cancer DU145 cells
7 (1), 5081
DOI 10.1038/s41598-017-05086-6, PubMed 28698547
Correction: MtDNA depleted PC3 cells exhibit Warburg effect and cancer stem cell features
8 (4), 7208-7213
DOI 10.18632/oncotarget.14800, PubMed 28179591
Frequent somatic mutations of KMT2D (MLL2) and CARD11 genes in primary cold agglutinin disease
183 (5), 838-842
DOI 10.1111/bjh.15063, PubMed 29265349
Folliculotropic Mycosis Fungoides with Skewed T-cell Receptor CDR3 Motif: Suggestive of Lipid-antigen Selection?
97 (9), 1081-1086
DOI 10.2340/00015555-2722, PubMed 28597017
A Selective Biomarker Panel Increases the Reproducibility and the Accuracy in Endometrial Biopsy Diagnosis
Int. J. Gynecol. Pathol., 36 (4), 339-347
DOI 10.1097/PGP.0000000000000334
NEIL3-Dependent Regulation of Cardiac Fibroblast Proliferation Prevents Myocardial Rupture
18 (1), 82-92
DOI 10.1016/j.celrep.2016.12.009, PubMed 28052262
Fusion of the genes ataxin 2 like, ATXN2L, and Janus kinase 2, JAK2, in cutaneous CD4 positive T-cell lymphoma
8 (61), 103775-103784
DOI 10.18632/oncotarget.21790, PubMed 29262599
Early introduction of oral paricalcitol in renal transplant recipients. An open-label randomized study
30 (8), 827-840
DOI 10.1111/tri.12973, PubMed 28436117
European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer Surgery
Int. J. Gynecol. Cancer, 27 (7), 1534-1542
DOI 10.1097/IGC.0000000000001041
Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate
2 (2), e000158
DOI 10.1136/esmoopen-2017-000158, PubMed 28761742
Involvement of DPP9 in gene fusions in serous ovarian carcinoma
17 (1), 642
DOI 10.1186/s12885-017-3625-6, PubMed 28893231
Epithelial-mesenchymal transition markers in malignant ovarian germ cell tumors
125 (9), 781-786
DOI 10.1111/apm.12715, PubMed 28585395
Rearrangement of the Chromatin Organizer Special AT-rich Binding Protein 1 Gene, SATB1, Resulting from a t(3;5)(p24;q14) Chromosomal Translocation in Acute Myeloid Leukemia
37 (2), 693-698
DOI 10.21873/anticanres.11365, PubMed 28179318
Publications 2016
Expressions of miR-30c and let-7a are inversely correlated with HMGA2 expression in squamous cell carcinoma of the vulva
7 (51), 85058-85062
DOI 10.18632/oncotarget.13187, PubMed 27835588
A novel truncated form of HMGA2 in tumors of the ovaries
12 (2), 1559-1563
DOI 10.3892/ol.2016.4805, PubMed 27446471
The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era
175 (1), 102-14
DOI 10.1111/bjh.14201, PubMed 27341313
TSAP6 is a novel candidate marker of poor survival in metastatic high-grade serous carcinoma
60, 180-187
DOI 10.1016/j.humpath.2016.10.017, PubMed 27825812
Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group
123 (7), 1095-1105
DOI 10.1002/cncr.30380, PubMed 27984660
Recently identified drug resistance biomarkers in ovarian cancer
16 (5), 569-78
DOI 10.1586/14737159.2016.1156532, PubMed 26895188
Malignant Nonhematological Effusion Characterization by Flow Cytometry
60 (4), 365-371
DOI 10.1159/000447687, PubMed 27532128
CD24 is highly useful in differentiating high-grade serous carcinoma from benign and malignant mesothelial cells
58, 123-127
DOI 10.1016/j.humpath.2016.08.005, PubMed 27589896
Progesterone Receptor Expression Is an Independent Prognosticator in FIGO Stage I Uterine Leiomyosarcoma
145 (4), 449-58
DOI 10.1093/ajcp/aqw030, PubMed 27149024
BAG-1/SODD, HSP70, and HSP90 are potential prognostic markers of poor survival in node-negative breast carcinoma
54, 64-73
DOI 10.1016/j.humpath.2016.02.023, PubMed 27038683
Expression and clinical significance of Wee1 in colorectal cancer
37 (9), 12133-12140
DOI 10.1007/s13277-016-5081-3, PubMed 27220319
hvTRA, a novel TRAIL receptor agonist, induces apoptosis and sustained growth retardation in melanoma
2, 16081
DOI 10.1038/cddiscovery.2016.81, PubMed 28028438
Ezrin Is Associated with Disease Progression in Ovarian Carcinoma
11 (9), e0162502
DOI 10.1371/journal.pone.0162502, PubMed 27622508
Ovarian Cancer Chemoresistance Relies on the Stem Cell Reprogramming Factor PBX1
76 (21), 6351-6361
DOI 10.1158/0008-5472.CAN-16-0980, PubMed 27590741
Genomewide copy number analysis of Müllerian adenosarcoma identified chromosomal instability in the aggressive subgroup
29 (9), 1070-82
DOI 10.1038/modpathol.2016.99, PubMed 27255164
REG4 Is Highly Expressed in Mucinous Ovarian Cancer: A Potential Novel Serum Biomarker
11 (3), e0151590
DOI 10.1371/journal.pone.0151590, PubMed 26981633
MtDNA depleted PC3 cells exhibit Warburg effect and cancer stem cell features
7 (26), 40297-40313
DOI 10.18632/oncotarget.9610, PubMed 27248169
Cytogenetic and molecular profile of endometrial stromal sarcoma
55 (11), 834-46
DOI 10.1002/gcc.22380, PubMed 27219024
Pre-analytical issues in effusion cytology
Pleura Peritoneum, 1 (1), 45-56
DOI 10.1515/pap-2016-0001
Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling
129 (6), 759-770
DOI 10.1182/blood-2016-05-718494, PubMed 28011673
MiR-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma
54, 74-81
DOI 10.1016/j.humpath.2016.03.010, PubMed 27063471
European Society of Gynaecologic Oncology Quality Indicators for Advanced Ovarian Cancer Surgery
Int. J. Gynecol. Cancer, 26 (7), 1354-1363
DOI 10.1097/IGC.0000000000000767
Uterine leiomyosarcoma and endometrial stromal sarcoma have unique miRNA signatures
140 (3), 512-7
DOI 10.1016/j.ygyno.2016.01.001, PubMed 26768834
Bilateral ovarian carcinomas differ in the expression of metastasis-related genes
13 (1), 184-190
DOI 10.3892/ol.2016.5384, PubMed 28123539
L1CAM as a prognostic marker in stage I endometrial cancer: a validation study
16, 596
DOI 10.1186/s12885-016-2631-4, PubMed 27488577
Novel Mad2-targeting miR-493-3p controls mitotic fidelity and cancer cells' sensitivity to paclitaxel
7 (11), 12267-85
DOI 10.18632/oncotarget.7860, PubMed 26943585
Reproducibility of measurement of myometrial invasion in endometrial carcinoma
470 (1), 63-68
DOI 10.1007/s00428-016-2035-5, PubMed 27787595
An integrated approach to infer dynamic protein-gene interactions - A case study of the human P53 protein
110, 3-13
DOI 10.1016/j.ymeth.2016.08.001, PubMed 27514497
Publications 2015
HMGA2 expression pattern and TERT mutations in tumors of the vulva
33 (6), 2675-80
DOI 10.3892/or.2015.3882, PubMed 25823555
Intra-Gene DNA Methylation Variability Is a Clinically Independent Prognostic Marker in Women's Cancers
10 (12), e0143178
DOI 10.1371/journal.pone.0143178, PubMed 26629914
Prognostic factors in malignant pleural mesothelioma
46 (6), 789-804
DOI 10.1016/j.humpath.2015.02.006, PubMed 25824607
HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival
48, 95-101
DOI 10.1016/j.humpath.2015.09.027, PubMed 26640230
MMP-7 is a highly specific negative marker for benign and malignant mesothelial cells in serous effusions
47 (1), 104-8
DOI 10.1016/j.humpath.2015.08.020, PubMed 26520416
Bilateral uveal melanomas with different gene expression detected with 7 years interval
94 (1), 99-102
DOI 10.1111/aos.12857, PubMed 26496992
Cellular localization of CIP2A determines its prognostic impact in superficial spreading and nodular melanoma
4 (6), 903-13
DOI 10.1002/cam4.425, PubMed 25663244
Guidelines for cytopathologic diagnosis of epithelioid and mixed type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology
12, 26
DOI 10.4103/1742-6413.170726, PubMed 26681974
Guidelines for the Cytopathologic Diagnosis of Epithelioid and Mixed-Type Malignant Mesothelioma: a secondary publication
26 (3), 142-56
DOI 10.1111/cyt.12250, PubMed 26052757
Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma: Complementary Statement from the International Mesothelioma Interest Group, Also Endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology
43 (7), 563-76
DOI 10.1002/dc.23271, PubMed 26100969
Guidelines for the Cytopathologic Diagnosis of Epithelioid and Mixed-Type Malignant Mesothelioma
Acta Cytol., 59 (1), 2-16
DOI 10.1159/000377697
Editorial: Advances in Epithelial Ovarian Cancer: Model Systems, Microenvironmental Influences, Therapy, and Origins
5, 205
DOI 10.3389/fonc.2015.00205, PubMed 26442217
Mitochondrial DNA Deficiency in Ovarian Cancer Cells and Cancer Stem Cell-like Properties
35 (7), 3743-53
PubMed 26124317
Mitochondrial DNA Deficiency in Ovarian Cancer Cells and Cancer Stem Cell-like Properties
Anticancer Res., 35 (7), 3743-3753
Hsp70 (HSPA1) Lysine Methylation Status as a Potential Prognostic Factor in Metastatic High-Grade Serous Carcinoma
10 (10), e0140168
DOI 10.1371/journal.pone.0140168, PubMed 26448330
MicroRNAs in Ovarian Cancer
46 (9), 1245-56
DOI 10.1016/j.humpath.2015.06.013, PubMed 26216350
Protein expression of BIRC5, TK1, and TOP2A in malignant peripheral nerve sheath tumours--A prognostic test after surgical resection
9 (6), 1129-39
DOI 10.1016/j.molonc.2015.02.005, PubMed 25769404
Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma
15, 462
DOI 10.1186/s12885-015-1474-8, PubMed 26054341
Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR)
28 (8), 1101-22
DOI 10.1038/modpathol.2015.77, PubMed 26089092
Extra-adrenal composite phaeochromocytoma/neuroblastoma in a 15-month-old child
J. Pediatr. Surg. Case Rep., 3 (8), 348-350
DOI 10.1016/j.epsc.2015.06.014
Extra-adrenal composite phaechromocytoma/neuroblastoma in a 15-month-old child
Journal of Pediatric Surgery CASE REPORTS, 3, 348-350
PublikaID 226
Expression and clinical role of chemoresponse-associated genes in ovarian serous carcinoma
139 (1), 30-9
DOI 10.1016/j.ygyno.2015.07.107, PubMed 26232338
CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma
14, 44
DOI 10.1186/s12943-015-0317-1, PubMed 25889687
KIT in melanoma: many shades of gray
135 (2), 337-338
DOI 10.1038/jid.2014.417, PubMed 25573046
Immunomodulatory effects of the Agaricus blazei Murrill-based mushroom extract AndoSan in patients with multiple myeloma undergoing high dose chemotherapy and autologous stem cell transplantation: a randomized, double blinded clinical study
2015, 718539
DOI 10.1155/2015/718539, PubMed 25664323
HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer
7, 108
DOI 10.1186/s13073-015-0233-4, PubMed 26497652
Novel ZEB2-BCL11B Fusion Gene Identified by RNA-Sequencing in Acute Myeloid Leukemia with t(2;14)(q22;q32)
10 (7), e0132736
DOI 10.1371/journal.pone.0132736, PubMed 26186352
BayesPI-BAR: a new biophysical model for characterization of regulatory sequence variations
43 (21), e147
DOI 10.1093/nar/gkv733, PubMed 26202972
Comprehensive genome-wide transcription factor analysis reveals that a combination of high affinity and low affinity DNA binding is needed for human gene regulation
BMC Genomics, 16 7, S12
DOI 10.1186/1471-2164-16-S7-S12
Integrated Study to Infer Dynamic Protein-gene Interactions in human P53 Regulatory Networks
IEEE INT C BIOINFORM, 273-276
Expression of CDK1(Tyr15), pCDK1(Thr161), Cyclin B1 (total) and pCyclin B1(Ser126) in vulvar squamous cell carcinoma and their relations with clinicopatological features and prognosis
10 (4), e0121398
DOI 10.1371/journal.pone.0121398, PubMed 25849598
Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules
28 (1), 82-96
DOI 10.1016/j.ccell.2015.05.009, PubMed 26096845
Publications 2014
BRAF-mutations in non-small cell lung cancer
84 (1), 36-8
DOI 10.1016/j.lungcan.2014.01.023, PubMed 24552757
The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions
46 (1), 1-8
DOI 10.1016/j.humpath.2014.10.004, PubMed 25455994
BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma
464 (6), 701-7
DOI 10.1007/s00428-014-1577-7, PubMed 24756216
VICKZ2 protein expression in ovarian serous carcinoma effusions is associated with poor survival
45 (7), 1520-8
DOI 10.1016/j.humpath.2014.03.005, PubMed 24814803
Ovarian cancer: diagnostic, biological and prognostic aspects
10 (5), 519-33
DOI 10.2217/whe.14.37, PubMed 25335543
The clinical and diagnostic role of microRNAs in ovarian carcinoma
133 (3), 640-6
DOI 10.1016/j.ygyno.2014.03.575, PubMed 24713546
The role of the tumor stroma in ovarian cancer
4, 104
DOI 10.3389/fonc.2014.00104, PubMed 24860785
Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification
112 (2), 290-5
DOI 10.1038/bjc.2014.557, PubMed 25356804
Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma
56 (6), 1742-9
DOI 10.3109/10428194.2014.970550, PubMed 25284491
Mnk2 alternative splicing modulates the p38-MAPK pathway and impacts Ras-induced transformation
7 (2), 501-513
DOI 10.1016/j.celrep.2014.03.041, PubMed 24726367
Prognostic biomarkers in endometrial and ovarian carcinoma
Virchows Arch., 464 (3), 315-331
DOI 10.1007/s00428-013-1509-y
MEAF6/PHF1 is a recurrent gene fusion in endometrial stromal sarcoma
347 (1), 75-8
DOI 10.1016/j.canlet.2014.01.030, PubMed 24530230
Genomic profile of ovarian carcinomas
14, 315
DOI 10.1186/1471-2407-14-315, PubMed 24886194
Low frequency of ESRRA-C11orf20 fusion gene in ovarian carcinomas
12 (2), e1001784
DOI 10.1371/journal.pbio.1001784, PubMed 24504521
Novel TNS3-MAP3K3 and ZFPM2-ELF5 fusion genes identified by RNA sequencing in multicystic mesothelioma with t(7;17)(p12;q23) and t(8;11)(q23;p13)
357 (2), 502-9
DOI 10.1016/j.canlet.2014.12.002, PubMed 25484136
Biomedical informatics and computational biology for high-throughput data analysis
2014, 398181
DOI 10.1155/2014/398181, PubMed 24688384
Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions
135 (1), 118-24
DOI 10.1016/j.ygyno.2014.07.102, PubMed 25093290
Chromosome 19 rearrangements in ovarian carcinomas: zinc finger genes are particularly targeted
53 (7), 558-67
DOI 10.1002/gcc.22166, PubMed 24634323
APOA1 mRNA expression in ovarian serous carcinoma effusions is a marker of longer survival
142 (1), 51-7
DOI 10.1309/AJCPD8NBSHXRXQL7, PubMed 24926085
Exosome-derived miRNAs and ovarian carcinoma progression
35 (9), 2113-20
DOI 10.1093/carcin/bgu130, PubMed 24925027
Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker
14, 80
DOI 10.1186/1471-2407-14-80, PubMed 24512620
Quality versus accuracy: result of a reanalysis of protein-binding microarrays from the DREAM5 challenge by using BayesPI2 including dinucleotide interdependence
15 (1), 289
DOI 10.1186/1471-2105-15-289, PubMed 25158938
Publications 2013
Translational Predictive Biomarker Analysis of the Phase 1b Sorafenib and Bevacizumab Study Expansion Cohort
Mol. Cell. Proteomics, 12 (6), 1621-1631
DOI 10.1074/mcp.M112.026427
S6K1 Alternative Splicing Modulates Its Oncogenic Activity and Regulates mTORC1
Cell Reports, 3 (1), 103-115
DOI 10.1016/j.celrep.2012.11.020
Hepatocyte nuclear factor-1β is not a specific marker of clear cell carcinoma in serous effusions
122 (2), 153-8
DOI 10.1002/cncy.21353, PubMed 24115587
Gene expression signatures of primary and metastatic uterine leiomyosarcoma
45 (4), 691-700
DOI 10.1016/j.humpath.2013.11.003, PubMed 24485798
Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion
44 (11), 2449-60
DOI 10.1016/j.humpath.2013.06.003, PubMed 24011953
Immunotoxin targeting EpCAM effectively inhibits peritoneal tumor growth in experimental models of mucinous peritoneal surface malignancies
133 (6), 1497-506
DOI 10.1002/ijc.28158, PubMed 23494569
Malignant phyllodes tumor and acute megakaryoblastic leukemia sharing a common clonal origin
2013, 934781
DOI 10.1155/2013/934781, PubMed 24455338
Histotype-Genotype Correlation in 36 High-grade Endometrial Carcinomas
Am. J. Surg. Pathol., 37 (9), 1421-1432
Treatment of children over the age of one year with unresectable localised neuroblastoma without MYCN amplification: Results of the SIOPEN study
Eur. J. Cancer, 49 (17), 3671-3679
DOI 10.1016/j.ejca.2013.07.002
High expression of wee1 is associated with malignancy in vulvar squamous cell carcinoma patients
13, 288
DOI 10.1186/1471-2407-13-288, PubMed 23767999
Genomic aberration patterns and expression profiles of squamous cell carcinomas of the vulva
52 (6), 551-63
DOI 10.1002/gcc.22053, PubMed 23404381
Fusion of the ZC3H7B and BCOR genes in endometrial stromal sarcomas carrying an X;22-translocation
52 (7), 610-8
DOI 10.1002/gcc.22057, PubMed 23580382
RNA sequencing identifies fusion of the EWSR1 and YY1 genes in mesothelioma with t(14;22)(q32;q12)
52 (8), 733-40
DOI 10.1002/gcc.22068, PubMed 23630070
Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma
99 (3), 497-504
DOI 10.3324/haematol.2013.091702, PubMed 24143001
Alternatively spliced lysyl oxidase-like 4 isoforms have a pro-metastatic role in cancer
Clin. Exp. Metastasis, 30 (1), 103-117
DOI 10.1007/s10585-012-9514-0
HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival
129 (2), 358-63
DOI 10.1016/j.ygyno.2013.02.021, PubMed 23438671
Peripheral neuroblastic tumors with genotype-phenotype discordance: A report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee
Pediatr. Blood Cancer, 60 (3), 363-370
DOI 10.1002/pbc.24238
Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer
EMBO Mol. Med., 5 (7), 1051-1066
DOI 10.1002/emmm.201201823
Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases
Hum. Pathol., 44 (12), 2677-2683
DOI 10.1016/j.humpath.2013.07.009
Proton magnetic resonance metabolomic characterization of ovarian serous carcinoma effusions: chemotherapy-related effects and comparison with malignant mesothelioma and breast carcinoma
44 (9), 1859-66
DOI 10.1016/j.humpath.2013.02.009, PubMed 23656974
Genome-wide analysis uncovers high frequency, strong differential chromosomal interactions and their associated epigenetic patterns in E2-mediated gene regulation
14, 70
DOI 10.1186/1471-2164-14-70, PubMed 23368971
Publications 2012
PRAME (preferentially expressed antigen of melanoma) is a novel marker for differentiating serous carcinoma from malignant mesothelioma
137 (2), 240-7
DOI 10.1309/AJCPGA95KVSAUDMF, PubMed 22261449
Rab25 is overexpressed in Müllerian serous carcinoma compared to malignant mesothelioma
460 (2), 193-202
DOI 10.1007/s00428-011-1191-x, PubMed 22249560
Gene expression signatures differentiate uterine endometrial stromal sarcoma from leiomyosarcoma
128 (2), 349-55
DOI 10.1016/j.ygyno.2012.11.021, PubMed 23178314
The diagnostic and research applications of flow cytometry in cytopathology
40 (6), 525-35
DOI 10.1002/dc.22809, PubMed 22619127
Migfilin, α-parvin and β-parvin are differentially expressed in ovarian serous carcinoma effusions, primary tumors and solid metastases
128 (2), 364-70
DOI 10.1016/j.ygyno.2012.10.015, PubMed 23099104
Epithelial-mesenchymal transition in ovarian carcinoma
2, 33
DOI 10.3389/fonc.2012.00033, PubMed 22655269
Prognostic significance of residual tumor in patients with epithelial ovarian carcinoma stage IV in a 20 year perspective
91 (3), 308-17
DOI 10.1111/j.1600-0412.2011.01316.x, PubMed 22050605
Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma
7 (9), e45492
DOI 10.1371/journal.pone.0045492, PubMed 23029050
[Invasive fungal infection]
132 (23-24), 2618
DOI 10.4045/tidsskr.12.0603, PubMed 23338093
Multidrug Resistance-Linked Gene Signature Predicts Overall Survival of Patients with Primary Ovarian Serous Carcinoma
Clin. Cancer Res., 18 (11), 3197-3206
DOI 10.1158/1078-0432.CCR-12-0056
HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases
460 (5), 505-13
DOI 10.1007/s00428-012-1228-9, PubMed 22476403
Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index
69 (5), 1307-14
DOI 10.1007/s00280-012-1835-9, PubMed 22302409
MGST1 expression in serous ovarian carcinoma differs at various anatomic sites, but is unrelated to chemoresistance or survival
126 (3), 460-5
DOI 10.1016/j.ygyno.2012.05.029, PubMed 22652154
Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance
44 (5), 777-85
DOI 10.1016/j.humpath.2012.08.002, PubMed 23114921
IKK-epsilon Coordinates Invasion and Metastasis of Ovarian Cancer
Cancer Res., 72 (21), 5494-5504
DOI 10.1158/0008-5472.CAN-11-3993
Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome
Cancer, 118 (6), 1543-1553
DOI 10.1002/cncr.26449
Ezrin and BCAR1/p130Cas mediate breast cancer growth as 3-D spheroids
Clin. Exp. Metastasis, 29 (6), 527-540
DOI 10.1007/s10585-012-9468-2
N-Cadherin in Neuroblastoma Disease: Expression and Clinical Significance
PLoS One, 7 (2), e31206
DOI 10.1371/journal.pone.0031206
High Expression of Wee1 Is Associated with Poor Disease-Free Survival in Malignant Melanoma: Potential for Targeted Therapy
PLoS One, 7 (6), e38254
DOI 10.1371/journal.pone.0038254
Synthetic retinoid CD437 induces apoptosis and acts synergistically with TRAIL receptor-2 agonist in malignant melanoma
420 (3), 516-22
DOI 10.1016/j.bbrc.2012.03.023, PubMed 22446330
Novel fusion of MYST/Esa1-associated factor 6 and PHF1 in endometrial stromal sarcoma
7 (6), e39354
DOI 10.1371/journal.pone.0039354, PubMed 22761769
Interleukin-33 drives a proinflammatory endothelial activation that selectively targets nonquiescent cells
33 (2), e47-55
DOI 10.1161/ATVBAHA.112.253427, PubMed 23162017
DNA ploidy may be a prognostic marker in stage I and II serous adenocarcinoma of the endometrium
461 (3), 291-8
DOI 10.1007/s00428-012-1275-2, PubMed 22824999
Narrowing the knowledge gaps for melanoma
Ups. J. Med. Sci., 117 (2), 237-243
DOI 10.3109/03009734.2012.658977
Cytoplasmic BRMS1 expression in malignant melanoma is associated with increased disease-free survival
12, 73
DOI 10.1186/1471-2407-12-73, PubMed 22356677
Low-dose anisomycin sensitizes melanoma cells to TRAIL induced apoptosis
14 (2), 146-54
DOI 10.4161/cbt.22953, PubMed 23192275
AZGP1 and SPDEF mRNA expression differentiates breast carcinoma from ovarian serous carcinoma
462 (2), 163-73
DOI 10.1007/s00428-012-1347-3, PubMed 23242172
Chronic lymphocytic leukaemia in Norway--incidence and prognostic markers at diagnosis
132 (18), 2056-9
DOI 10.4045/tidsskr.11.1349, PubMed 23038195
Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV?
48 (14), 2146-54
DOI 10.1016/j.ejca.2012.01.031, PubMed 22382201
Borderline ovarian tumours
26 (3), 325-36
DOI 10.1016/j.bpobgyn.2011.12.006, PubMed 22321906
Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma
Hum. Pathol., 43 (11), 2062-2069
DOI 10.1016/j.humpath.2012.02.016
Effective non-linear methods for inferring genetic regulation from time-series microarray gene expression data
802, 235-46
DOI 10.1007/978-1-61779-400-1_15, PubMed 22130884
Hyaluronan Synthase and Hyaluronidase Expression in Serous Ovarian Carcinoma is Related to Anatomic Site and Chemotherapy Exposure
Int. J. Mol. Sci., 13 (10), 12925-12938
DOI 10.3390/ijms131012925
Publications 2011
A Multilocus Technique for Risk Evaluation of Patients with Neuroblastoma
Clin. Cancer Res., 17 (4), 792-804
DOI 10.1158/1078-0432.CCR-10-0830
Nucleoside transporters are widely expressed in ovarian carcinoma effusions
69 (2), 467-75
DOI 10.1007/s00280-011-1716-7, PubMed 21822668
SCARA3 mRNA is overexpressed in ovarian carcinoma compared with breast carcinoma effusions
43 (5), 669-74
DOI 10.1016/j.humpath.2011.06.003, PubMed 21855113
Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status
32 (3), 589-96
DOI 10.1007/s13277-011-0157-6, PubMed 21350924
Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival
43 (4), 496-505
DOI 10.1016/j.humpath.2011.05.023, PubMed 21855111
Osteopontin expression in ovarian carcinoma effusions is related to improved clinical outcome
42 (7), 991-7
DOI 10.1016/j.humpath.2010.10.013, PubMed 21315424
Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions
15 (3), 535-44
DOI 10.1111/j.1582-4934.2010.01023.x, PubMed 20132413
Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions
J. Cell. Mol. Med., 15 (3), 535-544
DOI 10.1111/j.1582-4934.2010.01019.x
Gene expression signatures differentiate adenocarcinoma of lung and breast origin in effusions
43 (5), 684-94
DOI 10.1016/j.humpath.2011.06.015, PubMed 21937081
Flow cytometric measurement of cellular FLICE-inhibitory protein (c-FLIP) in ovarian carcinoma effusions
22 (6), 373-82
DOI 10.1111/j.1365-2303.2011.00929.x, PubMed 22032542
Heat shock protein 90 is a putative therapeutic target in patients with recurrent advanced-stage ovarian carcinoma with serous effusions
43 (4), 529-35
DOI 10.1016/j.humpath.2011.05.022, PubMed 21864883
Targeting inhibitor of apoptosis proteins in combination with dacarbazine or TRAIL in melanoma cells
12 (1), 47-58
DOI 10.4161/cbt.12.1.15714, PubMed 21508672
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance
Proc. Natl. Acad. Sci. U. S. A., 108 (46), 18708-18713
DOI 10.1073/pnas.1111840108
Clinical Relevance of Multidrug Resistance Gene Expression in Ovarian Serous Carcinoma Effusions
Mol. Pharm., 8 (6), 2080-2088
DOI 10.1021/mp200240a
Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance
42 (7), 1019-26
DOI 10.1016/j.humpath.2010.10.025, PubMed 21315408
Genome wide single cell analysis of chemotherapy resistant metastatic cells in a case of gastroesophageal adenocarcinoma
11, 455
DOI 10.1186/1471-2407-11-455, PubMed 22014070
Paracrine SLPI secretion upregulates MMP-9 transcription and secretion in ovarian cancer cells
Gynecol. Oncol., 122 (3), 656-662
DOI 10.1016/j.ygyno.2011.04.052
High Resolution Detection and Analysis of CpG Dinucleotides Methylation Using MBD-Seq Technology
PLoS One, 6 (7), e22226
DOI 10.1371/journal.pone.0022226
Mantle cell lymphoma with features of marginal-zone lymphoma
4 (1), 7-11
DOI 10.1007/s12308-011-0084-x, PubMed 25089161
Expression and Clinical Role of Protein of Regenerating Liver (PRL) Phosphatases in Ovarian Carcinoma
Int. J. Mol. Sci., 12 (2), 1133-1145
DOI 10.3390/ijms12021133
Prognostic variables in oligodendroglial tumors: a single-institution study of 95 cases
13 (11), 1225-33
DOI 10.1093/neuonc/nor114, PubMed 21856683
Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study)
Br. J. Cancer, 105 (12), 1940-1948
DOI 10.1038/bjc.2011.472
Immunocytochemistry in Europe: results of the European Federation of Cytology Societies (EFCS) inquiry
Cytopathology, 22 (4), 238-242
DOI 10.1111/j.1365-2303.2011.00885.x
miRNA profiling along tumour progression in ovarian carcinoma
J. Cell. Mol. Med., 15 (7), 1593-1602
DOI 10.1111/j.1582-4934.2010.01148.x
Computational study of associations between histone modification and protein-DNA binding in yeast genome by integrating diverse information
12, 172
DOI 10.1186/1471-2164-12-172, PubMed 21457549
PINCH-2 expression in cancers involving serosal effusions using quantitative PCR
22 (1), 22-9
DOI 10.1111/j.1365-2303.2010.00757.x, PubMed 20500520
Publications 2010
Nuclear Factor kappa B Transcription Factors Are Coexpressed and Convey a Poor Outcome in Ovarian Cancer
Cancer, 116 (13), 3276-3284
DOI 10.1002/cncr.25190
High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease
116 (17), 3180-4
DOI 10.1182/blood-2010-06-288647, PubMed 20634373
Expression and clinical role of growth differentiation factor-15 in ovarian carcinoma effusions
20 (9), 1448-55
DOI 10.1111/IGC.0b013e3181f7d6be, PubMed 21336029
Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma
41 (6), 794-804
DOI 10.1016/j.humpath.2009.09.017, PubMed 20153512
The diagnostic and molecular characteristics of malignant mesothelioma and ovarian/peritoneal serous carcinoma
22 (1), 5-21
DOI 10.1111/j.1365-2303.2010.00829.x, PubMed 21114695
New determinates of disease progression and outcome in metastatic ovarian carcinoma
25 (12), 1591-609
DOI 10.14670/HH-25.1591, PubMed 20886439
New determinates of disease progression and outcome in metastatic ovarian carcinoma
Histol. Histopath., 25 (12), 1591-1609
CD105 (Endoglin) expression in breast carcinoma effusions is a marker of poor survival
19 (6), 493-8
DOI 10.1016/j.breast.2010.05.013, PubMed 21078485
Meta-analysis of Neuroblastomas Reveals a Skewed ALK Mutation Spectrum in Tumors with MYCN Amplification
Clin. Cancer Res., 16 (17), 4353-4362
DOI 10.1158/1078-0432.CCR-09-2660
Measurement of apoptosis in cytological specimens by flow cytometry: comparison of Annexin V, caspase cleavage and dUTP incorporation assays
22 (6), 365-72
DOI 10.1111/j.1365-2303.2010.00811.x, PubMed 21054589
POLD2 and KSP37 (FGFBP2) correlate strongly with histology, stage and outcome in ovarian carcinomas
5 (11), e13837
DOI 10.1371/journal.pone.0013837, PubMed 21079801
Mesenchymal-to-epithelial transition determinants as characteristics of ovarian carcinoma effusions
Clin. Exp. Metastasis, 27 (3), 161-172
DOI 10.1007/s10585-010-9315-2
Exploring the peritoneal surface malignancy phenotype--a pilot immunohistochemical study of human pseudomyxoma peritonei and derived animal models
41 (8), 1109-19
DOI 10.1016/j.humpath.2009.12.013, PubMed 20338618
Activation of NF-KB Signaling by Inhibitor of NF-KB Kinase beta Increases Aggressiveness of Ovarian Cancer
Cancer Res., 70 (10), 4005-4014
DOI 10.1158/0008-5472.CAN-09-3912
Oncoproteomic Analysis Reveals Co-Upregulation of RELA and STAT5 in Carboplatin Resistant Ovarian Carcinoma
PLoS One, 5 (6), e11198
DOI 10.1371/journal.pone.0011198
Breast Carcinoma Cells in Primary Tumors and Effusions Have Different Gene Array Profiles
J. Oncol., 2010, 969084
DOI 10.1155/2010/969084
Genomic aberrations in borderline ovarian tumors
8, 21
DOI 10.1186/1479-5876-8-21, PubMed 20184781
Genome-wide transcription profile of endothelial cells after cardiac transplantation in the rat
10 (7), 1534-44
DOI 10.1111/j.1600-6143.2010.03157.x, PubMed 20642680
Biological effects induced by insulin-like growth factor binding protein 3 (IGFBP-3) in malignant melanoma
126 (2), 350-61
DOI 10.1002/ijc.24727, PubMed 19588500
Notch3 Overexpression Is Related to the Recurrence of Ovarian Cancer and Confers Resistance to Carboplatin
Am. J. Pathol., 177 (3), 1087-1094
DOI 10.2353/ajpath.2010.100316
DNA ploidy heterogeneity in endometrial carcinoma: comparison between curettage and hysterectomy specimens
29 (6), 572-8
DOI 10.1097/PGP.0b013e3181e2e8ee, PubMed 20881853
Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovarian carcinogenesis
Am. J. Obstet. Gynecol., 203 (6), 584.e1
DOI 10.1016/j.ajog.2010.08.003
Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer
118 (3), 237-43
DOI 10.1016/j.ygyno.2010.05.032, PubMed 20576287
Low levels of monoclonal small B cells in the bone marrow of patients with diffuse large B-cell lymphoma of activated B-cell type but not of germinal center B-cell type
Haematol-Hematol. J., 95 (8), 1334-1341
DOI 10.3324/haematol.2009.014100
Expression of Fatty Acid Synthase Depends on NAC1 and Is Associated with Recurrent Ovarian Serous Carcinomas
J. Oncol., 2010, 285191
DOI 10.1155/2010/285191
The effect of prior assumptions over the weights in BayesPI with application to study protein-DNA interactions from ChIP-based high-throughput data
11, 412
DOI 10.1186/1471-2105-11-412, PubMed 20684785
Quantitative model for inferring dynamic regulation of the tumour suppressor gene p53
11, 36
DOI 10.1186/1471-2105-11-36, PubMed 20085646
Molecular Genetic Markers in Female Reproductive Cancers
J. Oncol., 2010, 307460
DOI 10.1155/2010/307460
Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes
10, 233
DOI 10.1186/1471-2407-10-233, PubMed 20500813
Matched Gene Selection and Committee Classifier for Molecular Classification of Heterogeneous Diseases
J. Mach. Learn. Res., 11, 2141-2167
Netrin-4 is upregulated in breast carcinoma effusions compared to corresponding solid tumors
39 (8), 562-6
DOI 10.1002/dc.21424, PubMed 20730893
Publications 2009
Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force
100 (10), 1627-37
DOI 10.1038/sj.bjc.6605029, PubMed 19401690
Expression of the peroxisome proliferator-activated receptors-alpha, -beta, and -gamma in ovarian carcinoma effusions is associated with poor chemoresponse and shorter survival
40 (5), 705-13
DOI 10.1016/j.humpath.2008.09.019, PubMed 19157507
Evaluation of cell surface expression of phosphatidylserine in ovarian carcinoma effusions using the annexin-V/7-AAD assay: clinical relevance and comparison with other apoptosis parameters
132 (5), 756-62
DOI 10.1309/AJCPAVFA8J3KHPRS, PubMed 19846818
Expression and clinical role of antiapoptotic proteins of the bag, heat shock, and Bcl-2 families in effusions, primary tumors, and solid metastases in ovarian carcinoma
28 (3), 211-21
DOI 10.1097/PGP.0b013e31818b0f5e, PubMed 19620938
Enhanced levels of urokinase plasminogen activator and its soluble receptor in common variable immunodeficiency
131 (3), 438-46
DOI 10.1016/j.clim.2009.01.007, PubMed 19232508
Chemokines and common variable immunodeficiency; possible contribution of the fractalkine system (CX3CL1/CX3CR1) to chronic inflammation
Clin. Immunol., 130 (2), 151-161
DOI 10.1016/j.clim.2008.09.002
Chemokines and common variable immunodeficiency; possible contribution of CCL19, CCL21 and CCR7 to immune dysregulation
158 (2), 237-45
DOI 10.1111/j.1365-2249.2009.04013.x, PubMed 19747210
Cell survival and apoptosis-related molecules in cancer cells in effusions: a comprehensive review
37 (8), 613-24
DOI 10.1002/dc.21095, PubMed 19418469
Cleaved caspase-3 and nuclear factor-kappaB p65 are prognostic factors in metastatic serous ovarian carcinoma
40 (6), 795-806
DOI 10.1016/j.humpath.2008.10.019, PubMed 19157506
Different expression and clinical role of S100A4 in serous ovarian carcinoma at different anatomic sites
30 (1), 15-25
DOI 10.1159/000199447, PubMed 19194111
t(3;21)(q22;q22) leading to truncation of the RYK gene in atypical chronic myeloid leukemia
277 (2), 205-11
DOI 10.1016/j.canlet.2008.12.016, PubMed 19168282
[Large granular lymphocytic leukaemia]
129 (11), 1098-102
DOI 10.4045/tidsskr.09.0152, PubMed 19488091
Gross genomic alterations differ between serous borderline tumors and serous adenocarcinomas--an image cytometric DNA ploidy analysis of 307 cases with histogenetic implications
454 (6), 677-83
DOI 10.1007/s00428-009-0778-y, PubMed 19421773
Large scale genomic instability as an additive prognostic marker in early prostate cancer
31 (4), 251-9
DOI 10.3233/CLO-2009-0463, PubMed 19633362
Lysyl oxidase-like 4 is alternatively spliced in an anatomic site-specific manner in tumors involving the serosal cavities
Virchows Arch., 454 (1), 71-79
DOI 10.1007/s00428-008-0694-6
Pathogenesis of ovarian cancer: clues from selected overexpressed genes
Future Oncol., 5 (10), 1641-1657
DOI 10.2217/FON.09.126
Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions
40 (4), 527-37
DOI 10.1016/j.humpath.2008.10.003, PubMed 19121847
Diagnosis and treatment of borderline ovarian neoplasms "the state of the art"
30 (5), 471-82
PubMed 19899396
Diagnosis and treatment of borderline ovarian neoplasms "the state of the art"
Eur. J. Gynaecol. Oncol., 30 (5), 471-482
Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study
Lancet Oncol., 10 (7), 663-671
DOI 10.1016/S1470-2045(09)70154-8
BayesPI - a new model to study protein-DNA interactions: a case study of condition-specific protein binding parameters for Yeast transcription factors
10, 345
DOI 10.1186/1471-2105-10-345, PubMed 19857274
Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions
40 (10), 1453-60
DOI 10.1016/j.humpath.2009.02.013, PubMed 19454358
Tenascin-X is a Novel Diagnostic Marker of Malignant Mesothelioma
Am. J. Surg. Pathol., 33 (11), 1673-1682
DOI 10.1097/PAS.0b013e3181b6bde3
Publications 2008
Jagged-1 and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion
Cancer Res., 68 (14), 5716-5723
DOI 10.1158/0008-5472.CAN-08-0001
MicroRNA Expression and Identification of Putative miRNA Targets in Ovarian Cancer
PLoS One, 3 (6), e2436
DOI 10.1371/journal.pone.0002436
New diagnostic and molecular characteristics of malignant mesothelioma
32 (6), 227-40
DOI 10.1080/01913120802454298, PubMed 19117264
The chemokine receptor CXCR4 is more frequently expressed in breast compared to other metastatic adenocarcinomas in effusions
14 (5), 476-82
DOI 10.1111/j.1524-4741.2008.00625.x, PubMed 18657145
Different clinical roles for p21-activated kinase-1 in primary and recurrent ovarian carcinoma
39 (11), 1630-6
DOI 10.1016/j.humpath.2008.03.009, PubMed 18656238
Expression of the chromatin remodeling factor Rsf-1 is down-regulated in breast carcinoma effusions
39 (4), 616-22
DOI 10.1016/j.humpath.2007.09.008, PubMed 18289639
Methods for simultaneous measurement of apoptosis and cell surface phenotype of epithelial cells in effusions by flow cytometry
3 (6), 955-64
DOI 10.1038/nprot.2008.77, PubMed 18546596
Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma
112 (1), 84-93
DOI 10.1002/cncr.23140, PubMed 17985388
Histogram analysis of MR imaging-derived cerebral blood volume maps: combined glioma grading and identification of low-grade oligodendroglial subtypes
29 (9), 1664-70
DOI 10.3174/ajnr.A1182, PubMed 18583405
FAP-alpha and uPA show different expression patterns in premalignant and malignant esophageal lesions
32 (3), 89-96
DOI 10.1080/01913120802034934, PubMed 18570153
Seprase, dipeptidyl peptidase IV and urokinase-type plasminogen activator expression in dysplasia and invasive squamous cell carcinoma of the esophagus. A study of 229 cases from Anyang Tumor Hospital, Henan Province, China
75 (1-2), 49-59
DOI 10.1159/000151741, PubMed 18787344
Dipeptidyl peptidase IV expression in cancer and stromal cells of human esophageal squamous cell carcinomas, adenocarcinomas and squamous cell carcinoma cell lines
116 (9), 823-31
DOI 10.1111/j.1600-0463.2008.01029.x, PubMed 19024603
Claudin upregulation in ovarian carcinoma effusions is associated with poor survival
39 (5), 747-57
DOI 10.1016/j.humpath.2007.10.002, PubMed 18439941
Ovarian carcinoma cells in effusions show increased S-phase fraction compared to corresponding primary tumors
36 (9), 637-44
DOI 10.1002/dc.20879, PubMed 18677760
1,5-disubstituted 1,2,3-triazoles as cis-restricted analogues of combretastatin A-4: Synthesis, molecular modeling and evaluation as cytotoxic agents and inhibitors of tubulin
Bioorg. Med. Chem., 16 (9), 4829-4838
DOI 10.1016/j.bmc.2008.03.049
Small Interfering RNA Molecules Targeting Endothelin-Converting Enzyme-1 Inhibit Endothelin-1 Synthesis and the Invasive Phenotype of Ovarian Carcinoma Cells
Cancer Res., 68 (22), 9265-9273
DOI 10.1158/0008-5472.CAN-08-2093
Can morphology predict 1p/19q loss in oligodendroglial tumours?
53 (5), 578-87
DOI 10.1111/j.1365-2559.2008.03160.x, PubMed 18983467
The fatty acid binding protein 7 (FABP7) is involved in proliferation and invasion of melanoma cells
8, 276
DOI 10.1186/1471-2407-8-276, PubMed 18826602
Human cytomegalovirus and Epstein-Barr virus in apical and marginal periodontitlits: A role in pathology.?
J. Med. Virol., 80 (6), 1007-1011
DOI 10.1002/jmv.21180
Fli-1 expression in malignant melanoma
Histol. Histopath., 23 (11), 1309-1314
Computational biology of genome expression and regulation--a review of microarray bioinformatics
27 (3), 157-79
DOI 10.1615/jenvironpatholtoxicoloncol.v27.i3.10, PubMed 18652564
Circulating calprotectin in ovarian carcinomas and borderline tumors of the ovary
198 (4), 418.e1-7
DOI 10.1016/j.ajog.2007.10.792, PubMed 18241816
Assessment of endoglin and calprotectin as potential biomarkers in ovarian carcinoma and borderline tumors of the ovary
199 (5), 533.e1-8
DOI 10.1016/j.ajog.2008.04.004, PubMed 18533117
Publications 2007
BAG-4/SODD and associated antiapoptotic proteins are linked to aggressiveness of epithelial ovarian cancer
13 (22 Pt 1), 6585-92
DOI 10.1158/1078-0432.CCR-07-0327, PubMed 18006758
Primary chronic cold agglutinin disease: an update on pathogenesis, clinical features and therapy
12 (5), 361-70
DOI 10.1080/10245330701445392, PubMed 17891600
Anatomic site-related expression of cancer-associated molecules in ovarian carcinoma
7 (1), 109-20
DOI 10.2174/156800907780006904, PubMed 17305482
Biological characteristics of cancers involving the serosal cavities
13 (3), 189-227
DOI 10.1615/critrevoncog.v13.i3.10, PubMed 18298385
Expression of cancer-associated molecules in malignant mesothelioma
2, 173-84
PubMed 19662202
Expression of Cancer-Associated Molecules in Malignant Mesothelioma
Biomark. Insights, 2, 173-184
MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells
35 (12), 756-60
DOI 10.1002/dc.20771, PubMed 18008338
Expression and clinical role of the bric-a-brac tramtrack broad complex/poxvirus and zinc protein NAC-1 in ovarian carcinoma effusions
38 (7), 1030-1036
DOI 10.1016/j.humpath.2006.12.009, PubMed 17391728
Chemokine receptors are infrequently expressed in malignant and benign mesothelial cells
127 (5), 752-9
DOI 10.1309/LN2075V7C8K31CH8, PubMed 17439834
Flow cytometric immunophenotyping of cancer cells in effusion specimens: diagnostic and research applications
35 (9), 568-78
DOI 10.1002/dc.20707, PubMed 17703449
Expression and clinical role of DJ-1, a negative regulator of PTEN, in ovarian carcinoma
39 (1), 87-95
DOI 10.1016/j.humpath.2007.05.014, PubMed 17949781
Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma
110 (6), 1264-71
DOI 10.1002/cncr.22918, PubMed 17647260
Kallikrein 4 is expressed in malignant mesothelioma--further evidence for the histogenetic link between mesothelial and epithelial cells
35 (2), 80-4
DOI 10.1002/dc.20588, PubMed 17230566
Flow cytometric immunphenotyping of epithelial cancer cells in effusions--technical considerations and pitfalls
72 (5), 332-43
DOI 10.1002/cyto.b.20172, PubMed 17226863
Survivin, a member of the inhibitors of apoptosis family, is down-regulated in breast carcinoma effusions
128 (3), 389-97
DOI 10.1309/E899BG1282M5D505, PubMed 17709312
Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma
109 (2), 228-38
DOI 10.1002/cncr.22426, PubMed 17167759
The diagnostic role of claudins in serous effusions
127 (6), 928-37
DOI 10.1309/V025QRN3R9CJGNPX, PubMed 17509990
Expression of inhibitor-of-apoptosis protein family members in malignant mesothelioma
38 (7), 986-994
DOI 10.1016/j.humpath.2006.12.013, PubMed 17350081
Molecular cytogenetic characterization of t(14;19)(q32;p13), a new recurrent translocation in B cell malignancies
450 (5), 559-65
DOI 10.1007/s00428-007-0407-6, PubMed 17406891
Characteristic appearances of the bone marrow in T-cell large granular lymphocyte leukaemia
50 (5), 547-54
DOI 10.1111/j.1365-2559.2007.02656.x, PubMed 17394489
Measurement of cyclin E genomic copy number and strand length in cell-free DNA distinguish malignant versus benign effusions
13 (19), 5805-9
DOI 10.1158/1078-0432.CCR-07-0853, PubMed 17908972
Molecular based treatment of oral cancer (Retraction of vol 39, pg 749, 2003)
Oral Oncol., 43 (4), 421
DOI 10.1016/j.oraloncology.2007.01.004
A new framework for identifying combinatorial regulation of transcription factors: A case study of the yeast cell cycle
J. Biomed. Inform., 40 (6), 707-725
DOI 10.1016/j.jbi.2007.02.003
Publications 2006
D2-40 is not a specific marker for cells of mesothelial origin in serous effusions
30 (7), 878-82
DOI 10.1097/01.pas.0000208280.29291.34, PubMed 16819331
Primary chronic cold agglutinin disease: a population based clinical study of 86 patients
Haematologica, 91 (4), 460-466
Primary chronic cold agglutinin disease: a population based clinical study of 86 patients
91 (4), 460-6
PubMed 16585012
Fine-needle aspiration cytology of the thyroid gland: comparative analysis of experience at three hospitals
34 (2), 97-100
DOI 10.1002/dc.20384, PubMed 16514672
Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling
12 (3 Pt 1), 791-9
DOI 10.1158/1078-0432.CCR-05-2516, PubMed 16467090
The mitogen-activated protein kinases (MAPK) p38 and JNK are markers of tumor progression in breast carcinoma
102 (3), 453-61
DOI 10.1016/j.ygyno.2006.01.034, PubMed 16494928
The biological differences between ovarian serous carcinoma and diffuse peritoneal malignant mesothelioma
23 (1), 35-43
DOI 10.1053/j.semdp.2006.06.003, PubMed 17044194
Heparanase expression correlates with poor survival in metastatic ovarian carcinoma
104 (2), 311-9
DOI 10.1016/j.ygyno.2006.08.045, PubMed 17030350
Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival
103 (3), 814-9
DOI 10.1016/j.ygyno.2006.05.042, PubMed 16844205
Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma
12 (20 Pt 1), 5944-50
DOI 10.1158/1078-0432.CCR-06-1059, PubMed 17062665
NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma
125 (3), 451-8
PubMed 16613351
NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma
Am. J. Clin. Pathol., 125 (3), 451-458
DOI 10.1309/15B66DQMFYYM78CJ
Expression of E-cadherin transcriptional regulators in ovarian carcinoma
449 (5), 520-8
DOI 10.1007/s00428-006-0274-6, PubMed 17024425
The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma
103 (3), 831-40
DOI 10.1016/j.ygyno.2006.06.042, PubMed 16919315
Doxorubicin levels in the serum and ascites of patients with ovarian cancer
33 (2), 213-5
DOI 10.1016/j.ejso.2006.11.006, PubMed 17174514
Polyclonal expansion of large granular lymphocytes in common variable immunodeficiency - association with neutropenia
144 (3), 418-24
DOI 10.1111/j.1365-2249.2006.03086.x, PubMed 16734610
Activation of c-jun N-terminal kinase is associated with cell proliferation and shorter relapse-free period in superficial spreading malignant melanoma
19 (11), 1446-55
DOI 10.1038/modpathol.3800662, PubMed 16951673
Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma
449 (1), 31-9
DOI 10.1007/s00428-005-0144-7, PubMed 16541284
Array comparative genomic hybridization reveals distinct DNA copy number differences between gastrointestinal stromal tumors and leiomyosarcomas
66 (18), 8984-93
DOI 10.1158/0008-5472.CAN-06-1972, PubMed 16982739
Homozygous deletion of MKK4 in ovarian serous carcinoma
5 (6), 630-4
DOI 10.4161/cbt.5.6.2675, PubMed 16627982
A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival
103 (49), 18739-44
DOI 10.1073/pnas.0604083103, PubMed 17130457
Prognostic value of International Neuroblastoma Pathology Classification in localized resectable peripheral neuroblastic tumors: a histopathologic study of localized neuroblastoma European Study Group 94.01 Trial and Protocol
24 (4), 695-9
DOI 10.1200/JCO.2004.00.8631, PubMed 16446343
Notch3 gene amplification in ovarian cancer
66 (12), 6312-8
DOI 10.1158/0008-5472.CAN-05-3610, PubMed 16778208
The p75 neurotrophin receptor is widely expressed in conventional papillary thyroid carcinoma
37 (5), 562-8
DOI 10.1016/j.humpath.2005.12.016, PubMed 16647954
Fluorescence in situ hybridization (FISH) on touch preparations: a reliable method for detecting loss of heterozygosity at 1p and 19q in oligodendroglial tumors
30 (7), 828-37
DOI 10.1097/01.pas.0000213250.44822.2e, PubMed 16819324
Cadherin expression in ovarian carcinoma and malignant mesothelioma cell effusions
50 (6), 603-7
DOI 10.1159/000326027, PubMed 17152269
Expression of Snail, Slug and Sip1 in malignant mesothelioma effusions is associated with matrix metalloproteinase, but not with cadherin expression
54 (3), 309-17
DOI 10.1016/j.lungcan.2006.08.010, PubMed 16996643
Pax-5 expression in nonhematopoietic tissues
Am. J. Clin. Pathol., 126 (5), 798-804
DOI 10.1309/XEC7JMW9YRM74RN0
Pax-5 expression in nonhematopoietic tissues
126 (5), 798-804
DOI 10.1309/XEC7-JMW9-YRM7-4RNO, PubMed 17050077
The activated nerve growth factor receptor p-TrkA is selectively expressed in advanced-stage ovarian carcinoma
38 (1), 140-6
DOI 10.1016/j.humpath.2006.06.027, PubMed 16996570
Publications 2005
Expression patterns of cell cycle components in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors
64 (1), 74-81
DOI 10.1093/jnen/64.1.74, PubMed 15715087
Detecting minimal residual disease in neuroblastoma patients-the present state of the art
228 (1-2), 229-40
DOI 10.1016/j.canlet.2005.02.053, PubMed 15951104
Identification and characterization of membralin, a novel tumor-associated gene, in ovarian carcinoma
1730 (2), 96-102
DOI 10.1016/j.bbaexp.2005.06.008, PubMed 16084606
Apolipoprotein E is required for cell proliferation and survival in ovarian cancer
65 (1), 331-7
PubMed 15665311
Apolipoprotein E is required for cell proliferation and survival in ovarian cancer
Cancer Res., 65 (1), 331-337
Primary ovarian angiosarcoma presenting as malignant cells in ascites: case report and review of the literature
32 (5), 307-9
DOI 10.1002/dc.20245, PubMed 15830366
HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma
96 (1), 42-7
DOI 10.1016/j.ygyno.2004.09.049, PubMed 15589578
Site-related expression of metastasis-associated and signaling molecules in malignant mesothelioma--a new model for the study of tumor biology and disease progression
49 Suppl 1, S89-93
DOI 10.1016/j.lungcan.2005.03.026, PubMed 15950809
Kallikrein 4 expression is up-regulated in epithelial ovarian carcinoma cells in effusions
123 (3), 360-8
DOI 10.1309/PTBB-5BPC-KX8K-9V69, PubMed 15716231
Kallikrein 4 expression is up-regulated in epithelial ovarian carcinoma cells in effusions
Am. J. Clin. Pathol., 123 (3), 360-368
DOI 10.1309/PTBB5BPCKX8K9V69
Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma
103 (8), 1631-43
DOI 10.1002/cncr.20946, PubMed 15742334
Laminin-induced signaling in tumor cells
223 (1), 1-10
DOI 10.1016/j.canlet.2004.08.030, PubMed 15890231
Phorbol ester phorbol-12-myristate-13-acetate promotes anchorage-independent growth and survival of melanomas through MEK-independent activation of ERK1/2
329 (1), 266-74
DOI 10.1016/j.bbrc.2005.01.143, PubMed 15721302
Angiogenic molecule expression is downregulated in effusions from breast cancer patients
94 (1), 71-80
DOI 10.1007/s10549-005-7328-3, PubMed 16142438
Differential expression of the 67 kilodalton laminin receptor in epithelioid malignant mesothelioma and carcinomas that spread to serosal cavities
33 (5), 332-7
DOI 10.1002/dc.20296, PubMed 16240397
Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients
4, 26
DOI 10.1186/1476-4598-4-26, PubMed 16042759
Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma
102 (39), 14004-9
DOI 10.1073/pnas.0504195102, PubMed 16172393
Quantitative analysis of integrin expression in effusions using flow cytometric immunophenotyping
33 (5), 325-31
DOI 10.1002/dc.20282, PubMed 16240402
Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome
124 (4), 528-36
DOI 10.1309/YT58WWMTA6YR1PRV, PubMed 16146807
Expression of xeroderma pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma
103 (11), 2313-9
DOI 10.1002/cncr.21031, PubMed 15844177
RETRACTED: Risk markers of oral cancer in clinically normal mucosa as an aid in smoking cessation counseling (Retracted Article. See vol 24, pg 5621, 2006)
J. Clin. Oncol., 23 (9), 1927-1933
DOI 10.1200/JCO.2005.03.172
Standardization of the immunocytochemical detection of neuroblastoma cells in bone marrow
J. Histochem. Cytochem., 53 (12), 1433-1440
DOI 10.1369/jhc.5C6661.2005
Potential application of ELAVL4 real-time quantitative reverse transcription-PCR for detection of disseminated neuroblastoma cells
52 (3), 438-45
DOI 10.1373/clinchem.2005.059485, PubMed 16384890
Mitogen-activated protein kinase expression and activation does not differentiate benign from malignant mesothelial cells
103 (11), 2427-33
DOI 10.1002/cncr.21014, PubMed 15830375
New probabilistic graphical models for genetic regulatory networks studies
38 (6), 443-55
DOI 10.1016/j.jbi.2005.04.003, PubMed 15996532
The AP-2gamma transcription factor is upregulated in advanced-stage ovarian carcinoma
100 (3), 462-8
DOI 10.1016/j.ygyno.2005.09.022, PubMed 16216317
Publications 2004
Expression of S100A4 combined with reduced E-cadherin expression predicts patient outcome in malignant melanoma
17 (8), 990-7
DOI 10.1038/modpathol.3800151, PubMed 15133476
Malignant effusions: from diagnosis to biology
31 (4), 246-54
DOI 10.1002/dc.20133, PubMed 15452897
Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma
100 (10), 2139-47
DOI 10.1002/cncr.20219, PubMed 15139056
The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions
21 (3), 191-9
DOI 10.1023/b:clin.0000037703.37275.35, PubMed 15387369
Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression
10 (21), 7335-46
DOI 10.1158/1078-0432.CCR-04-0183, PubMed 15534110
Altered expression and activation of the nerve growth factor receptors TrkA and p75 provide the first evidence of tumor progression to effusion in breast carcinoma
83 (2), 119-28
DOI 10.1023/B:BREA.0000010704.17479.8a, PubMed 14997042
Expression of the nerve growth factor receptors TrkA and p75 in malignant mesothelioma
44 (2), 159-65
DOI 10.1016/j.lungcan.2003.11.014, PubMed 15084380
Malignant mesothelioma
28 (4), 179-80
DOI 10.1080/01913120490518051, PubMed 15693629
Heparanase and basic fibroblast growth factor are co-expressed in malignant mesothelioma
21 (5), 469-76
DOI 10.1007/s10585-004-3150-2, PubMed 15672872
Expression of activated TrkA protein in melanocytic tumors - Relationship to cell proliferation and clinical outcome
Am. J. Clin. Pathol., 122 (3), 412-420
DOI 10.1309/CHFHEYAT44WWP7J3
Expression of activated TrkA protein in melanocytic tumors: relationship to cell proliferation and clinical outcome
122 (3), 412-20
DOI 10.1309/CHFH-EYAT-44WW-P7J3, PubMed 15362372
Deacetylase inhibition in malignant melanomas: impact on cell cycle regulation and survival
14 (3), 173-81
DOI 10.1097/01.cmr.0000129576.49313.26, PubMed 15179185
The PAC-1 dual specificity phosphatase predicts poor outcome in serous ovarian carcinoma
93 (2), 517-23
DOI 10.1016/j.ygyno.2004.03.009, PubMed 15099972
Laminin-induced signaling in tumor cells: the role of the M(r) 67,000 laminin receptor
64 (10), 3572-9
DOI 10.1158/0008-5472.CAN-03-3424, PubMed 15150114
Plasminogen activator inhibitor-1 increases the expression of VEGF in human glioma cells
294 (1), 130-9
DOI 10.1016/j.yexcr.2003.10.013, PubMed 14980508
The role of flow cytometric immunophenotyping in improving the diagnostic accuracy in referred fine-needle aspiration specimens
31 (3), 159-63
DOI 10.1002/dc.20108, PubMed 15349984
Ets-1 transcription factor is widely expressed in benign and malignant melanocytes and its expression has no significant association with prognosis
17 (11), 1400-6
DOI 10.1038/modpathol.3800206, PubMed 15205685
M-CGH: analysing microarray-based CGH experiments
5, 74
DOI 10.1186/1471-2105-5-74, PubMed 15189572
Kallikrein 4 is associated with paclitaxel resistance in ovarian cancer
94 (1), 80-5
DOI 10.1016/j.ygyno.2004.03.044, PubMed 15262123
Publications 2003
Fine-needle aspiration cytology vs. core biopsy in the diagnosis of breast lesions
29 (6), 344-8
DOI 10.1002/dc.10372, PubMed 14648793
Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): co-expression in metastatic serous ovarian carcinoma
20 (7), 621-31
DOI 10.1023/a:1027347932543, PubMed 14669793
EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma
20 (2), 161-9
DOI 10.1023/a:1022696012668, PubMed 12705637
PEA3 is the second Ets family transcription factor involved in tumor progression in ovarian carcinoma
9 (4), 1412-9
PubMed 12684413
PEA3 is the second Ets family transcription factor involved in tumor progression in ovarian carcinoma
Clin. Cancer Res., 9 (4), 1412-1419
Coordinated expression of integrin subunits, matrix metalloproteinases (MMP), angiogenic genes and Ets transcription factors in advanced-stage ovarian carcinoma: a possible activation pathway?
22 (1), 103-15
DOI 10.1023/a:1022272204045, PubMed 12716042
AlphaV- and beta1-integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients
90 (2), 248-57
DOI 10.1016/s0090-8258(03)00321-4, PubMed 12893184
Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma
Clin. Cancer Res., 9 (6), 2248-2259
Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma
9 (6), 2248-59
PubMed 12796393
Effusion cytology in ovarian cancer: new molecular methods as aids to diagnosis and prognosis
23 (3), 729-54, viii
DOI 10.1016/s0272-2712(03)00058-1, PubMed 14560537
Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions
91 (1), 160-72
DOI 10.1016/s0090-8258(03)00434-7, PubMed 14529677
Expression of the 67 kDa laminin receptor and the alpha6 integrin subunit in serous ovarian carcinoma
20 (7), 599-609
DOI 10.1023/a:1027340208536, PubMed 14669791
Expression of activated extracellular signal-regulated kinases 1/2 in malignant melanomas: relationship with clinical outcome
9 (14), 5325-31
PubMed 14614017
Reduced beta-catenin expression in the cytoplasm of advanced-stage superficial spreading malignant melanoma
9 (9), 3383-8
PubMed 12960126
Candidate genes for testicular cancer evaluated by in situ protein expression analyses on tissue microarrays
5 (5), 397-404
DOI 10.1016/s1476-5586(03)80042-8, PubMed 14670177
RETRACTED: Molecular based treatment of oral cancer (Retracted article. See vol 43, pg 421, 2007)
Oral Oncol., 39 (8), 749-758
DOI 10.1016/S1368-8375(03)00098-8
COX-2 expression in striated muscle under physiological conditions
9 (6), 313-6
DOI 10.1034/j.1601-0825.2003.00957.x, PubMed 14629333
Splenic marginal zone lymphoma with villous lymphocytes shows on-going immunoglobulin gene mutations
162 (2), 681-9
DOI 10.1016/S0002-9440(10)63862-X, PubMed 12547726
Tumor classification and marker gene prediction by feature selection and fuzzy c-means clustering using microarray data
4, 60
DOI 10.1186/1471-2105-4-60, PubMed 14651757
MGraph: graphical models for microarray data analysis
19 (17), 2210-1
DOI 10.1093/bioinformatics/btg298, PubMed 14630649
Publications 2002
Detection of malignant epithelial cells in effusions using flow cytometric immunophenotyping: an analysis of 92 cases
118 (1), 85-92
DOI 10.1309/M877-QABM-D9GB-FJAX, PubMed 12109861
Detection of malignant epithelial cells in effusions using flow cytometric immunophenotyping - An analysis of 92 cases
Am. J. Clin. Pathol., 118 (1), 85-92
Caveolin-1 expression in ovarian carcinoma is MDR1 independent
117 (2), 225-34
DOI 10.1309/u40r-1bn4-6kj3-bdg3, PubMed 11863219
Caveolin-1 expression in ovarian carcinoma is MDR1 independent
Am. J. Clin. Pathol., 117 (2), 225-234
The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma
187 (1-2), 39-45
DOI 10.1016/s0303-7207(01)00709-2, PubMed 11988310
Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions
19 (2), 135-44
DOI 10.1023/a:1014582911680, PubMed 11964077
The biological role and regulation of matrix metalloproteinases (MMP) in cancer
64 (3), 47-53
PubMed 15338725
Adenomatous polyposis coli (APC) protein expression in primary and metastatic serous ovarian carcinoma
10 (3), 175-80
DOI 10.1177/106689690201000302, PubMed 12232570
Positional cloning identifies a novel cyclophilin as a candidate amplified oncogene in 1q21
21 (14), 2261-9
DOI 10.1038/sj.onc.1205339, PubMed 11948409
Clinical and cell line specific expression profiles of a human gene identified in experimental central nervous system metastases
22 (4), 1949-57
PubMed 12174869
Dissociated expression of Bcl-2 and Ki-67 in endometrial lesions: diagnostic and histogenetic implications
21 (2), 155-60
DOI 10.1097/00004347-200204000-00008, PubMed 11917225
Fine-needle aspiration cytology of lobular carcinoma in situ
27 (1), 22-6
DOI 10.1002/dc.10128, PubMed 12112810
Cystic change in metastatic lymph nodes: a common diagnostic pitfall in fine-needle aspiration cytology
27 (6), 387-92
DOI 10.1002/dc.10201, PubMed 12451573
Clustering of the SOM easily reveals distinct gene expression patterns: results of a reanalysis of lymphoma study
3, 36
DOI 10.1186/1471-2105-3-36, PubMed 12445336
MArray: analysing single, replicated or reversed microarray experiments
18 (8), 1139-40
DOI 10.1093/bioinformatics/18.8.1139, PubMed 12176840
Publications 2001
Reduced expression of plakoglobin correlates with adverse outcome in patients with neuroblastoma
159 (1), 43-9
DOI 10.1016/S0002-9440(10)61671-9, PubMed 11438452
Infertility treatment after conservative management of borderline ovarian tumors
92 (2), 320-5
DOI 10.1002/1097-0142(20010715)92:2<320::aid-cncr1325>3.0.co;2-g, PubMed 11466685
Ovarian carcinoma and serous effusions. Changing views regarding tumor progression and review of current literature
23 (3-4), 107-28
DOI 10.1155/2001/418547, PubMed 12082292
Expression of membrane-type 1, 2, and 3 matrix metalloproteinases messenger RNA in ovarian carcinoma cells in serous effusions
115 (4), 517-24
DOI 10.1309/B1YX-L8DB-TGY1-7905, PubMed 11293899
Expression of membrane-type 1, 2, and 3 matrix metalloproteinases messenger RNA in ovarian carcinoma cells in serous effusions
Am. J. Clin. Pathol., 115 (4), 517-524
Expression of angiogenesis-related genes in ovarian carcinoma - A clinicopathologic study
Clin. Exp. Metastasis, 18 (6), 501-507
Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients
7 (11), 3457-64
PubMed 11705863
Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients
Clin. Cancer Res., 7 (11), 3457-3464
Caveolin-1 expression in advanced-stage ovarian carcinoma--a clinicopathologic study
81 (2), 166-71
DOI 10.1006/gyno.2001.6156, PubMed 11330944
The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells
25 (11), 1405-12
DOI 10.1097/00000478-200111000-00008, PubMed 11684957
Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels
37 (16), 2040-9
DOI 10.1016/s0959-8049(01)00235-0, PubMed 11597382
Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma
7 (3), 551-7
PubMed 11297247
Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma
Clin. Cancer Res., 7 (3), 551-557
Expression of cell cycle proteins in ovarian carcinoma cells in serous effusions-biological and prognostic implications
83 (2), 249-56
DOI 10.1006/gyno.2001.6388, PubMed 11606079
Ets-1 mRNA expression in effusions of serous ovarian carcinoma patients is a marker of poor outcome
25 (12), 1493-500
DOI 10.1097/00000478-200112000-00004, PubMed 11717538
Plasmacytoid dendritic cells (natural interferon- alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions
159 (1), 237-43
DOI 10.1016/s0002-9440(10)61689-6, PubMed 11438470
Cyclin A expression in superficial spreading malignant melanomas correlates with clinical outcome
195 (5), 530-6
DOI 10.1002/path.1007, PubMed 11745687
Amplification and overexpression of PRUNE in human sarcomas and breast carcinomas-a possible mechanism for altering the nm23-H1 activity
20 (47), 6881-90
DOI 10.1038/sj.onc.1204874, PubMed 11687967
Granulocyte colony-stimulating factor receptor mutations in a patient with acute lymphoblastic leukemia secondary to severe congenital neutropenia
97 (3), 829-30
DOI 10.1182/blood.v97.3.829, PubMed 11227095
Alphav integrin expression is a novel marker of poor prognosis in advanced-stage ovarian carcinoma
7 (12), 4073-9
PubMed 11751504
alpha v integrin expression is a novel marker of poor prognosis in advanced-stage ovarian carcinoma
Clin. Cancer Res., 7 (12), 4073-4079
Topoisomerase II immunostaining as a prognostic marker for survival in ovarian cancer
82 (1), 99-104
DOI 10.1006/gyno.2001.6208, PubMed 11426969
Reduced expression of p21WAF1 is an indicator of malignant behaviour in anal carcinomas
39 (1), 43-9
DOI 10.1046/j.1365-2559.2001.01161.x, PubMed 11454043
Detection of monocyte/macrophage cell populations in effusions: a comparative study using flow cytometric immunophenotyping and immunocytochemistry
25 (4), 214-9
DOI 10.1002/dc.2041, PubMed 11599103
Publications 2000
Expression of CD44 in effusions of patients diagnosed with serous ovarian carcinoma--diagnostic and prognostic implications
18 (2), 197-202
DOI 10.1023/a:1006711320107, PubMed 11235996
Differential expression of CD44s and CD44v3-10 in adenocarcinoma cells and reactive mesothelial cells in effusions
Virchows Arch., 436 (4), 330-335
DOI 10.1007/s004280050455
[Serous effusions]
120 (3), 367-72
PubMed 10827531
E-cadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions
J. Pathol., 192 (4), 460-469
Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: Evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions
Hum. Pathol., 31 (9), 1081-1087
DOI 10.1053/hupa.2000.9776
Expression of topoisomerase II and Ki-67 in cervical carcinoma - clinicopathological study using immunohistochemistry
APMIS, 108 (3), 209-215
DOI 10.1034/j.1600-0463.2000.d01-46.x
Expression of carbohydrate antigens in advanced-stage ovarian carcinomas and their metastases - A clinicopathologic study
Gynecol. Oncol., 77 (1), 35-43
DOI 10.1006/gyno.1999.5708
E-cadherin complex protein expression and survival in ovarian carcinoma
Gynecol. Oncol., 79 (3), 362-371
DOI 10.1006/gyno.2000.5964
Co-induction of Mad1 and c-Myc in activated normal B lymphocytes
Scand. J. Immunol., 51 (6), 565-570
Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma
6 (9), 3614-20
PubMed 10999753
Flow cytometric immunophenotyping of serous effusions and peritoneal washings: comparison with immunocytochemistry and morphological findings
53 (7), 513-7
DOI 10.1136/jcp.53.7.513, PubMed 10961174
A splice variant of human ephrin-A4 encodes a soluble molecule that is secreted by activated human B lymphocytes
Blood, 95 (1), 221-230
DOI 10.1182/blood.V95.1.221.001k01_221_230
Publications 1999
High-dose therapy supported with immunomagnetic purged autologous bone marrow in high-grade B cell non-Hodgkin's lymphoma
Bone Marrow Transplant., 24 (8), 865-872
DOI 10.1038/sj.bmt.1701990
Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells
Cytotherapy, 1 (5), 377-388
DOI 10.1080/0032472031000141283
High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma
Clin. Exp. Metastasis, 17 (10), 799-808
DOI 10.1023/A:1006723011835
MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma - A clinicopathologic study using immunohistochemistry and mRNA in situ hybridization
Gynecol. Oncol., 73 (3), 372-382
DOI 10.1006/gyno.1999.5381
Evaluation of lymphoid cell populations in cytology specimens using flow cytometry and polymerase chain reaction
Diagn. Mol. Pathol., 8 (4), 183-188
DOI 10.1097/00019606-199912000-00003
Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies - Evaluation of five epithelial markers
Virchows Arch. Int. J. Pathol., 435 (1), 43-49
DOI 10.1007/s004280050393
Expression of metalloproteinases endometrial stromal sarcoma: immunohistochemical study using image analysis
J. Clin. Pathol., 52 (3), 198-202
DOI 10.1136/jcp.52.3.198
Publications 1998
Immunocytochemical detection of isolated epithelial cells in bone marrow: Non-specific staining and contribution by plasma cells directly reactive to alkaline phosphatase
J. Pathol., 185 (4), 427-434
DOI 10.1002/(SICI)1096-9896(199808)185:4<427::AID-PATH127>3.0.CO;2-7
Expression of metalloproteinases and their inhibitors in adenocarcinoma of the uterine cervix
Int. J. Gynecol. Pathol., 17 (4), 295-301
DOI 10.1097/00004347-199810000-00002
Increased sensitivity for detection of micrometastases in bone-marrow/peripheral-blood stem-cell products from breast-cancer patients by negative immunomagnetic separation
Int. J. Cancer, 78 (5), 556-560
Increased sensitivity for detection of micrometastases in bone-marrow/peripheral-blood stem-cell products from breast-cancer patients by negative immunomagnetic separation
78 (5), 556-60
DOI 10.1002/(sici)1097-0215(19981123)78:5<556::aid-ijc5>3.0.co;2-g, PubMed 9808522
Publications 1997
Differential expression patterns of S100A2, S100A4 and S100A6 during progression of human malignant melanoma
74 (4), 464-9
DOI 10.1002/(sici)1097-0215(19970822)74:4<464::aid-ijc19>3.0.co;2-9, PubMed 9291441
Immunomagnetic techniques for the enrichment and detection of isolated breast carcinoma cells in bone marrow and peripheral blood
J. Hematother., 6 (2), 103-114
DOI 10.1089/scd.1.1997.6.103
CDw78 - a determinant on a major histocompatibility complex class II subpopulation that can be induced to associate with the cytoskeleton
Eur. J. Immunol., 27 (12), 3206-3213
DOI 10.1002/eji.1830271218
Publications 1996
Antigen-presenting function of human peritoneum mesothelial cells isolated from a pancreatic carcinoma patient after mutant Ras peptide vaccination
Cancer Immunol. Immunother., 43 (5), 262-268
[High-dose therapy of cancer with CD34 positive cells as stem cell support]
116 (21), 2542-6
PubMed 8928121
[Human T-cell lymphotrophic virus type I and T-cell lymphoma]
116 (2), 238-41
PubMed 8633332
Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas
73 (8), 909-16
DOI 10.1038/bjc.1996.181, PubMed 8611425
Reversal of the in vivo metastatic phenotype of human tumor cells by an anti-CAPL (mts1) ribozyme
56 (23), 5490-8
PubMed 8968106
Publications 1995
TGF-BETA-1 AND CYCLIC-AMP PROMOTE APOPTOSIS IN RESTING HUMAN B-LYMPHOCYTES
J. Immunol., 154 (4), 1634-1643
TGF-beta 1 and cyclic AMP promote apoptosis in resting human B lymphocytes
154 (4), 1634-43
PubMed 7836748
Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas--relationship to amplification and mRNA levels of CDK4 and CCND1
72 (2), 393-8
DOI 10.1038/bjc.1995.344, PubMed 7640224
Publications 1993
p53 abnormalities in different subtypes of human sarcomas
53 (3), 468-71
PubMed 8425179
Publications 1992
DETECTION OF BONE-MARROW METASTASES IN SMALL-CELL LUNG-CANCER PATIENTS - COMPARISON OF IMMUNOLOGICAL AND MORPHOLOGICAL METHODS
Am. J. Pathol., 141 (3), 531-538
CELL CYCLE-DEPENDENT REGULATION OF CDW75 (BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE) ON HUMAN LYMPHOCYTES-B
Eur. J. Immunol., 22 (5), 1149-1155
DOI 10.1002/eji.1830220507
[Immunophenotyping of leukemias]
112 (18), 2373-4
PubMed 1412241
AN EFFECTIVE IMMUNOMAGNETIC METHOD FOR BONE-MARROW PURGING IN T-CELL MALIGNANCIES
Bone Marrow Transplant., 9 (5), 319-323
Publications 1991
T-CELL RECEPTOR TAU-DELTA+/CD3+4-8- T-CELL ACUTE LYMPHOBLASTIC LEUKEMIAS - A DISTINCT SUBGROUP OF LEUKEMIAS IN CHILDREN - A REPORT OF 5 CASES
Blood, 77 (9), 2023-2030
T-cell receptor tau delta +/CD3+4-8-T- cell acute lymphoblastic leukemias: a distinct subgroup of leukemias in children. A report of five cases
77 (9), 2023-30
PubMed 1826854
SELECTION OF ANTI-SCLC ANTIBODIES FOR DIAGNOSIS OF BONE-MARROW METASTASIS
Br. J. Cancer, 63 14, 49-53
INTERLEUKIN-7 DIFFERENTIATES A SUBGROUP OF ACUTE LYMPHOBLASTIC LEUKEMIAS
Blood, 77 (11), 2445-2450
IMMUNOHISTOLOGICAL DIAGNOSIS OF PLASMACYTOID T-CELL LYMPHOMA IN PARAFFIN WAX SECTIONS
J. Clin. Pathol., 44 (8), 632-635
DOI 10.1136/jcp.44.8.632
Publications 1990
IMMUNOLOGICAL TYPING OF ACUTE LEUKEMIAS BY ROSETTING WITH IMMUNOMAGNETIC BEADS - COMPARISON WITH IMMUNOFLUORESCENCE STAINING
Scand. J. Immunol., 31 (5), 567-573
DOI 10.1111/j.1365-3083.1990.tb02807.x
Publications 1989
LOW-GRADE INTESTINAL LYMPHOMA OF INTRAEPITHELIAL LYMPHOCYTES-T WITH CONCOMITANT ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA - CASE-REPORT SUGGESTING A POSSIBLE HISTOGENETIC RELATIONSHIP
Hum. Pathol., 20 (9), 909-913
Intracellular events associated with inhibition of B cell activation by monoclonal antibodies to HLA class II antigens
19 (7), 1221-5
DOI 10.1002/eji.1830190711, PubMed 2547623
Ki67 and 4F2 antigen expression as well as DNA synthesis predict survival at relapse/tumour progression in low-grade B-cell lymphoma
44 (6), 975-80
DOI 10.1002/ijc.2910440605, PubMed 2606582
Publications 1988
TRIGGERING OF NEOPLASTIC B-CELLS VIA SURFACE IGM AND THE CELL-SURFACE ANTIGENS CD20 AND CDW40 - RESPONSES DIFFER FROM NORMAL BLOOD B-CELLS AND ARE RESTRICTED TO CERTAIN MORPHOLOGIC SUBSETS
Int. J. Cancer, 42 (4), 521-528
DOI 10.1002/ijc.2910420409
SUCCESSFUL CLINICAL USE OF AN ANTI-HLA-DR MONOCLONAL-ANTIBODY FOR AUTOLOGOUS BONE-MARROW TRANSPLANTATION
JNCI-J. Natl. Cancer Inst., 80 (16), 1322-1325
DOI 10.1093/jnci/80.16.1322
IMMUNOLOGICAL TYPING OF ACUTE LEUKEMIAS - IMMUNOENZYMATIC STAINING OF FIXED CELLS COMPARED WITH IMMUNOFLUORESCENCE STAINING OF UNFIXED CELLS IN SUSPENSION
Eur. J. Haematol., 41 (2), 147-155
Publications 1987
SINGLE CELL STUDIES ON THE IMMUNOLOGICAL MARKER PROFILE OF PLASMACYTOID T-ZONE CELLS
Lab. Invest., 56 (4), 381-393
Cyclic AMP-mediated suppression of normal and neoplastic B cell proliferation is associated with regulation of myc and Ha-ras protooncogenes
131 (3), 426-33
DOI 10.1002/jcp.1041310315, PubMed 3036888
REGULATION OF C-MYC TRANSCRIPTION AND PROTEIN EXPRESSION DURING ACTIVATION OF NORMAL HUMAN B-CELLS
Exp. Cell Res., 172 (1), 101-109
DOI 10.1016/0014-4827(87)90097-8
ACTIVATION OF HUMAN B-CELLS - ALTERNATE OPTIONS FOR INITIAL TRIGGERING AND EFFECTS OF NONMITOGENIC CONCENTRATIONS OF ANTI-IGM ANTIBODIES ON RESTING AND ACTIVATED CELLS
J. Immunol., 138 (10), 3179-3184
TRANSFORMING GROWTH-FACTOR TYPE-BETA (TGF-BETA) INHIBITS G1 TO S TRANSITION, BUT NOT ACTIVATION OF HUMAN LYMPHOCYTES-B
Exp. Cell Res., 171 (1), 213-222
DOI 10.1016/0014-4827(87)90264-3
Publications 1986
T-ZONE LYMPHOMA WITH PREDOMINANCE OF PLASMACYTOID T-CELLS ASSOCIATED WITH MYELOMONOCYTIC LEUKEMIA - A DISTINCT CLINICOPATHOLOGICAL ENTITY
J. Pathol., 150 (4), 247-255
DOI 10.1002/path.1711500404
CHARACTERIZATION OF HUMAN MONONUCLEAR-CELLS AFTER POSITIVE SELECTION WITH IMMUNOMAGNETIC PARTICLES
Scand. J. Immunol., 23 (4), 509-519
REGULATION OF C-MYC MESSENGER-RNA AND PROTEIN-LEVELS DURING ACTIVATION OF NORMAL HUMAN B-CELLS
Curr.Top.Microbiol.Immunol., 132, 290-296
Publications 1985
THE SPECIFIC INDUCTION OF MYC PROTOONCOGENE EXPRESSION IN NORMAL HUMAN B-CELLS IS NOT A SUFFICIENT EVENT FOR ACQUISITION OF COMPETENCE TO PROLIFERATE
Proc. Natl. Acad. Sci. U. S. A., 82 (18), 6255-6259
DOI 10.1073/pnas.82.18.6255
Publications 1984
INDUCTION OF MATURATION OF HUMAN B-CELL LYMPHOMAS INVITRO - MORPHOLOGIC CHANGES IN RELATION TO IMMUNOGLOBULIN AND DNA-SYNTHESIS
Am. J. Pathol., 115 (3), 362-374
INDUCTION OF MATURATION IN DIFFERENT TYPES OF B-CELL LYMPHOMAS INVITRO WITH TPA AND ANTIBODIES TO SURFACE-IMMUNOGLOBULIN
Scand. J. Immunol., 20 (3), 199-208
DOI 10.1111/j.1365-3083.1984.tb00993.x
Different fate of antibodies to surface IgM and IgD in germinal centre cell-associated lymphomas
19 (5), 447-55
DOI 10.1111/j.1365-3083.1984.tb00953.x, PubMed 6427920
Publications 1983
Different responses elicited in vitro by antibodies to IgM and IgD in cells from a surface IgM + D-positive human follicular lymphoma
17 (2), 155-60
DOI 10.1111/j.1365-3083.1983.tb00778.x, PubMed 6340180
Publications 1982
RHINOSPORIDIOSIS AFFECTING THE PALPEBRAL CONJUNCTIVA - A CASE-REPORT
Ethiop. Med. J., 20 (3), 135-139